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ABSTRACT OF DISSERTATION 
 
 
NOVEL POST-TRANSLATIONAL MODIFICATION AND FUNCTION 
OF FUS: THE RELEVANCE TO AMYOTROPHIC LATERAL SCLEROSIS 
 
 
Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease 
characterized by the preferential death of motor neurons. Approximately 10% of 
ALS cases are familial and 90% are sporadic. Fused in Sarcoma (FUS) is a 
ubiquitously expressed RNA binding protein implicated in familial ALS and 
frontotemporal dementia (FTD). FUS is ubiquitously expressed in cells and has a 
variety of functions in the nucleus and cytoplasm. FUS mutations in the nuclear 
localization sequence (NLS) causes mislocalization of FUS in the cytoplasm, 
where it can undergo liquid-liquid phase separation and become stress granules 
or protein inclusions. Although FUS inclusion bodies can be found in post-mortem 
tissues from ALS patients, the pathological mechanism of the disease remains to 
be fully elucidated.  
 
This dissertation includes two independent studies about FUS regulation and 
function in the cell. In the first study, we discovered a novel post-translational 
modification, i.e. lysine acetylation on FUS and aimed to understand whether 
lysine acetylation plays a role in regulating FUS function. We identified three 
acetylation sites in FUS: K315/K316 in the RRM domain and K510 in the NLS. We 
found that K510 disrupted the interaction with Transportin-1 and increased 
cytoplasmic protein aggregates that co-localized with stress granule markers. 
Interestingly, acetylation in K315/K316 reduced RNA binding to FUS and 
decreased the cytoplasmic inclusion formation. Similarly, treatment with 
deacetylase inhibitors also decreased protein aggregation in cells expressing ALS 
mutation P525L. Furthermore, ALS patient derived fibroblasts showed higher 
levels of acetylation at K510, compared to healthy controls. Finally, we 
demonstrated that CBP/p300 acetylates FUS, while both HDACs and Sirtuins 
contribute to FUS deacetylation. We concluded that FUS acetylation regulates 
RNA binding, subcellular localization, and inclusion formation, linking acetylation 
of FUS to a potential molecular mechanism for ALS/FTD. 
  
   
 
 
The second study aimed to determine the function of FUS in the autophagy 
pathway. We found that mutant FUS did not affect autophagy flux in N2A cells. 
However, FUS knockout (KO) N2A cells showed a significant decrease in the basal 
autophagy flux compared to wild-type (WT) cells. Bafilomycin A1 treatment 
showed a decrease in autophagy flux in FUS KO cells, and induction of autophagy 
by rapamycin was not as efficient in FUS KO cells compared to WT cells. These 
results suggest that FUS KO affects early stages of the autophagy pathway. We 
found that FIP200, ATG16L1, and ATG12 gene and protein expression levels were 
significantly lower in FUS KO cells. FIP200 is involved in autophagy initiation and 
Atg16 and Atg12 form a complex to induce phagophore elongation. 
Overexpressing WT FUS in FUS KO cells was able to rescue gene and protein 
expression levels of FIP200 and ATG16L1. These findings demonstrate a novel 
function of FUS in regulating transcription of genes involved in early stages of the 
autophagy pathway. Failure to maintain protein homeostasis by protein 
degradation has been demonstrated in neurodegenerative diseases and finding 
new protein targets can be useful to discover new therapeutic options for ALS.  
 
The two studies of this dissertation produce novel findings of FUS protein 
modification and function. Each study provides new insights into the role of FUS in 
neurodegenerative diseases including ALS and FTD, as well as novel therapeutic 
targets. Future studies that determine the molecular mechanisms connecting 
these two findings will be necessary to evaluate how FUS acetylation and inclusion 
formation will impact the autophagy pathway. 
 
 
KEYWORDS: FUS, lysine acetylation, autophagy, stress granules, cytoplasmic 
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CHAPTER 1. LYSINE ACETYLATION REGULATES THE RNA BINDING, 
SUBCELLULAR LOCALIZATION AND INCLUSION FORMATION OF FUS 
Modified from the manuscript “Lysine acetylation regulates the RNA 
binding, subcellular localization and inclusion formation of FUS” published in 
Human Molecular Genetics, 21 July 2020. PMID: 32691043 
https://doi.org/10.1093/hmg/ddaa159 
1.1 Abstract 
Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease 
characterized by the preferential death of motor neurons. Approximately 10% 
of ALS cases are familial and 90% are sporadic. Fused in Sarcoma (FUS) is a 
ubiquitously expressed RNA binding protein implicated in familial ALS and 
frontotemporal dementia (FTD). The physiological function and pathological 
mechanism of FUS are not well understood, particularly whether post-
translational modifications play a role in regulating FUS function. In this study, 
we discovered that FUS was acetylated at lysine-315/316 (K315/K316) and 
lysine-510 (K510) residues in two distinct domains. Located in the nuclear 
localization sequence, K510 acetylation disrupted the interaction between 
FUS and Transportin-1, resulting in the mis-localization of FUS in the 
cytoplasm and formation of stress granule-like inclusions. Located in the RNA 
recognition motif, K315/K316 acetylation reduced RNA binding to FUS and 
decreased the formation of cytoplasmic inclusions. Treatment with 
deacetylase inhibitors also significantly reduced the inclusion formation in cells 
expressing ALS mutation P525L. More interestingly, familial ALS patient 
fibroblasts showed higher levels of FUS K510 acetylation as compared to 
healthy controls. Lastly, CBP/p300 acetylated FUS, whereas both SIRT and 
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HDAC families of lysine deacetylases contributed to FUS deacetylation. These 
findings demonstrate that FUS acetylation regulates the RNA binding, 
subcellular localization, and inclusion formation of FUS, implicating a potential 
role of acetylation in the pathophysiological process leading to FUS-mediated 
ALS/FTD.  
1.2 Introduction 
1.2.1 Amyotrophic Lateral Sclerosis 
Amyotrophic lateral sclerosis (ALS) is a progressive neurological 
disorder characterized by the gradual degeneration of motor neurons leading 
to progressive weakening of muscles, paralysis and death [1]. Motor neurons 
are cells that reach the brain, brain stem, and spinal cord, and they 
communicate the nervous system with the voluntary muscles of the body [1]. 
In ALS, when motor neurons degenerate and die, signals from the brain are 
unable to reach the muscles, and as a consequence, the muscles waste away 
and patients lose their ability to move their arms and legs, to talk, and to 
breathe. Eventually, patients need respiratory support, and most people die 
from respiratory failure or pneumonia [2].   
 
1.2.2 Epidemiology of ALS 
According to the ALS association, more than 5,000 people are 
diagnosed with ALS each year, and about 16,000 people live with ALS at any 
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given time in the United States [3]. The National ALS registry reported that the 
prevalence of ALS in the United States was 5.2 per 100,000 population in 2015 
[3]. The median age of ALS diagnosis is between 54 and 69 years old [4], and 
the median survival from the symptoms onset is approximately 2-3 years. The 
ratio of cases between males and females is 1.6:1 [3]. The ratio of cases 
between Caucasians and African Americans is approximately 2.3:1 in the 
United States [3]. Interestingly, there is evidence supporting that people who 
serve in the military have a higher risk of developing ALS [5]. In addition, 
smoking, head trauma, exposure to lead and other heavy metals, and 
exposure to agricultural chemicals are considered potential risk factors of 
developing ALS [6]. However, the relationship between the environmental 
factors and development of the disease has been difficult to identify because 
most of the times, the environmental exposure can change over time and may 
not have been accurately recorded [7].  
 
1.2.3 Sporadic and familial ALS 
ALS was initially considered a sporadic disease as Jean-Martin Charcot 
initially supported the notion [8]. Years later, there was a report of a family in 
Vermont with autosomal dominant inheritance of ALS [9]. Nowadays, it has 
been shown that most cases of ALS are sporadic (~ 90%), while the remaining 
10% of the cases are inherited [2, 3]. The clinical characteristics of ALS are 
similar whether it is inherited or sporadic [10]. Studying familial cases of ALS 
allows to gain insights about the pathology of the disease in general, and it will 
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likely benefit patients with sporadic forms of ALS. Mutations in several genes 
have been identified to cause the familial form of ALS (fALS) [4]. For instance, 
an hexanucleotide repeat expansion in the chromosome 9 open reading frame 
72 gene (C9orf72) accounts for about 30%-40% of the familial cases of ALS 
[11, 12]. Generally, a person has 30 or fewer GGGGCC repeats. However ALS 
or frontotemporal degeneration (FTD) patients may carry hundreds or 
thousands of GGGGCC repeats, and these expansions are often associated 
with behavioral changes [7]. Copper-zinc superoxide dismutase (SOD1), is an 
antioxidant enzyme that protects cells against superoxide radicals and reactive 
oxygen species (ROS) [13]. About 20% of familial cases of ALS have 
mutations in SOD1 [2]. Many studies suggest that SOD1 mutations cause ALS 
in a gain-of-function manner. The first supporting evidence was done in a 
transgenic mouse model expressing the point mutation G93A SOD1 [14]. The 
mice showed motor neuron loss and became paralyzed by 5-6 months of age 
[14]. Additional studies of transgenic mice expressing other human SOD1 
mutations show an adult-onset phenotype along with a loss of lower motor 
neurons [15]. Nonetheless, it was also proposed that the loss-of-function might 
play a minor role in the disease [16]. 
Another gene involved in familial ALS is TARDBP, the gene that 
encodes the TAR DNA-binding protein 43 (TDP-43). Mutations in this gene 
account for 4% of familial ALS and 1% of sporadic ALS cases [10]. However, 
approximately 97% of ALS cases, including familial and sporadic, show TDP-
43-positive inclusions. The TDP-43 proteinopathy [17] is characterized by the 
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exclusion of TDP-43 from the nucleus and the deposition of full-length and 
fragmented TDP-43 in cytoplasmic aggregates that are also ubiquitinated and 
hyperphosphorylated [18]. TDP-43 is a DNA/RNA binding protein that has the 
ability to shuttle between the nucleus and the cytoplasm [19]. In the nucleus it 
has been reported to be involved in transcription and splicing [17, 20]. In the 
cytoplasm it has a role in RNA transport [21] and stress granule response [22].  
It is unclear whether TDP-43 causes ALS by a gain or loss of function. 
A few studies show that TDP-43 overexpression mimics the disease 
phenotype in transgenic mice models [23, 24]. However, conditional TDP-43 
KO mouse models have demonstrated that loss of TDP-43 also causes motor 
neuron degeneration, very similar to the human phenotype along with TDP-43 
proteinopathy [25, 26]. Currently, it is considered in the field that both 
mechanisms may contribute to the development of the disease [17, 27].  
Furthermore, mutations in Fused in Sarcoma (FUS, also called 
Translocated in Liposarcoma or TLS) are found in about 5% of the familial 
cases of ALS  [28]. FUS pathology and mutations have also been reported in 
sporadic ALS cases [28-31]. Mutations in the FUS gene are associated with 
juvenile and young adult cases of sporadic ALS [32-34]. Moreover, FUS 
pathology is reported in approximately 10% cases of another clinically 
overlapping disease frontotemporal dementia (FTD-FUS) [30]. FUS is also a 
DNA/RNA binding protein with diverse functions in the cell [35]. Our lab 
focuses on the function of FUS and how mutations and post-translational 
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modifications affect the function of this protein and its association with the 
development of ALS and FTD. 
 
1.2.4 Fused in Sarcoma (FUS)  
FUS is a ubiquitously expressed RNA-binding protein that plays a role 
in different cellular processes such as DNA repair [36-38], transcription [39-
49], RNA splicing [48, 50, 51], nucleo-cytoplasmic RNA shuttling [52] and 
dendritic RNA transport [53-55]. FUS contains a very transcriptionally active  
N-terminal prion-like domain, (QGSY-rich), an RNA recognition motif (RRM), 
a zinc finger domain flanked by two Arginine-Glycine-Glycine (RGG)-rich 
domains, a nuclear export sequence (NES), and a C-terminal nuclear 
localization sequence (NLS) [27] (Figure 1.1). FUS is mainly localized in the 
nucleus, although it is also present in the cytoplasm of neuronal cells at lower 
levels [28].  Many of the fALS–related FUS mutations are localized in the C-
terminal NLS, causing mis-localization of FUS to the cytoplasm where it forms 
stress granule-like structures [29-32]. A loss of FUS function in the nucleus 
and a gain of toxic function in the cytoplasm can both contribute to the disease 
mechanism concomitantly [33]. 
 
1.2.5 Physiological roles of FUS in the nucleus 
Several groups have characterized the functions of FUS in the cell. 
Since FUS localizes mainly in the nucleus, it has been reported to play crucial 
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roles in transcription, miRNA processing, splicing, and DNA damage 
response. For instance, FUS has been reported to bind DNA and RNA through 
their RRM domain, the RGG-rich domain, and the zinc finger domains [36, 56, 
57]. A common ‘GGUG’ RNA consensus sequence has been identified to bind 
FUS [56], but more recent studies have reported that FUS can bind G/C or A/C 
rich regions [58, 59]. Another study confirmed that FUS binds long regions in 
the 3’ UTR of Nd1-L mRNA [53], suggesting that FUS can recognize other 
RNA binding domains from other proteins and bind to secondary structures. 
Additionally, FUS also plays a role in transcription. Numerous studies 
have found that FUS interacts with transcription factors [49, 60] hormone 
receptors [61], and the transcriptional machinery that includes RNA 
polymerase II and the TFIID complex [62, 63]. Similarly, FUS has been shown 
to repress transcription of Cyclin D1 in response to DNA damage, by being 
recruited into the promoter region, and inhibiting the activity of the 
acetyltransferases CREB-binding protein (CBP) and p300 on Cyclin D1 [39]. 
Another study reported that FUS N-terminal QGSY-rich region is required for 
active-chromatin binding, and for transcription activation of MnSOD and 
histone-lysine N-methyltransferase, SMYD3. The same study added that FUS’ 
self-assembly is necessary for chromatin binding, and that FUS ALS mutants 
disrupt these functions [48]. These data show that FUS is capable of binding 
RNA, transcriptional machinery, and active chromatin, having a relevant role 
in gene transcription. 
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Similarly, FUS has been found to be involved in microRNA (miRNA) 
processing. There is evidence that miRNAs might play a protective role in 
motor neurons and promote motor neuron survival [64, 65]. Specifically, mice 
that lacked miR-218 died at birth with motor neuron defects [66]. Additionally, 
motor neurons derived from a spinal muscular atrophy patient showed 
downregulation of miR-375, and these motor neurons were highly susceptible 
to DNA damage [65]. Moreover, in a transcriptome analysis, miR-375 was 
deregulated in mutant FUS motor neurons, while toxic expression of apoptotic 
factor p53 and neural RNA-binding protein ELAVL4, increased significantly in 
FUS mutants [67]. FUS has been directly associated to miRNA biogenesis by 
enabling the recruitment of the enzyme Drosha to chromatin transcription 
sites, and by interacting with nascent pri-miRNAs, in order to allow effective 
miRNA processing [68].  Together, these studies show that FUS plays an 
important role in miRNA biogenesis, having an impact in post-transcriptional 
gene regulation.   
Furthermore, FUS is involved in alternative splicing. Proteomics studies 
have found that FUS is present in the spliceosome [69, 70]. Also, sequencing 
analysis have showed that FUS is enriched in exons that are actively 
undergoing alternative splicing [59, 71]. Interestingly, a group found that FUS 
binds to a conserved region in exon 7 of its own pre-mRNA. [72]. The study 
showed that FUS overexpression caused inhibition of exon 7 splicing and 
downregulation of endogenous FUS protein levels, showing a mechanism for 
FUS autoregulation. In contrast, cytoplasmic FUS mutants were unable to 
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repress exon 7 splicing and regulate protein expression [72], showing that FUS 
nuclear localization is necessary for alternative splicing and FUS 
autoregulation.  
Additionally, FUS interacts with alternative splicing regulators such as 
SMN (survival motor neuron), and U1 snRNP [73]. SMN is highly expressed in 
spinal cord and brainstem, and mutations in this protein cause Spinal Muscular 
Atrophy (SMA)[74] . SMN is part of a complex that plays an important role in 
mRNA processing [75].  In the cells, this protein localizes to nuclear gems, 
which are nuclear structures where small nuclear ribonucleoprotein (snRNP) 
maturation takes place [74]. The relationship between FUS and SMN has been 
widely studied, since these two proteins have a crucial role in 
neurodegeneration. Specifically, ALS-associated FUS mutations sequester 
SMN into cytoplasmic inclusions, inhibiting the function of SMN in the nucleus 
and reducing the number of nuclear gems. Similarly, HeLa FUS knockout cells 
also show loss of nuclear gems [73]. In a similar study, FUS ALS mutations 
increased the interaction between FUS and SMN, causing a decrease in 
number of nuclear gems and a lower levels of snRNAs [76]. These studies 
demonstrate that FUS plays an important role in mRNA biogenesis and 
splicing, and show that a gain of toxic function, along with a loss of nuclear 




1.2.6 Physiological roles of FUS in the cytoplasm.  
FUS has the capacity of shuttling between the nucleus and the 
cytoplasm, where it can regulate different facets of RNA metabolism such as 
protein translation, RNA stability, RNA transport, or stress granule formation. 
The involvement of FUS in RNA transport has been reported in various 
studies. For example, a proteomics study found that FUS interacts with kinesin 
KIF5, a protein that is part of an RNA-transporting granule [77]. Additionally, 
another study showed that following NMDA activation, FUS requires actin 
filaments and microtubules to translocate to dendritic spines and is involved in 
preserving spine morphology and stabilizing synaptic structure by transporting 
mRNAs that encode for Nd1-L, an actin-stabilizing protein. [53, 54]. These 
studies show that FUS has an important role in transporting RNA to active 
translation spots in the cytoplasm, and this function is crucial for the good 
development of neuronal cells.  
An early study found that FUS associates with adenomatous polyposis 
coli (APC), and it is required for translation of APC-ribonucleoprotein (APC-
RNPs) transcripts in cell protrusions [78]. They show that aggregates formed 
as a result of mutant FUS overexpression recruit APC-RNPs, and these 
aggregates are transcriptionally active. Later on, a breakthrough mass 
spectrometry study showed that FUS is involved in protein translation and non-
sense mediated decay (NMD) [79]. They found that cytoplasmic mutant FUS 
inclusions contained proteins involved in translation and RNA surveillance. 
Furthermore, using a variety of assays, they proved that FUS ALS mutations 
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impaired global protein translation. Additionally, they demonstrated that 
translation initiation was not affected by FUS mutations. Interestingly, NMD 
factors were disrupted in N2A cells overexpressing FUS mutants and in ALS-
patients derived fibroblasts, leading to over activation of the NMD pathway. 
This study suggests that FUS has an important role in protein biosynthesis and 
mRNA quality control.  
A more recent work using proteomics compared the translated 
proteomes of WT and mutant FUS after being exposed to stress. They 
identified a great number of neurodegeneration-related proteins that become 
unregulated by avoiding stress induced translational repression [80]. One of 
the target proteins they found to be downregulated in mutant FUS cells under 
stress was COPB1, a protein involved in the retrograde transport between the 
Golgi apparatus and the endoplasmic reticulum (ER), showing that vesicular 
transport can also be impacted in FUS-ALS.  
Cytoplasmic FUS is also involved in stress granule dynamics and 
inclusion formation. WT cytoplasmic FUS can be chaperoned back to the 
nucleus by Transportin-1 (TNPO1), through a direct interaction with FUS-NLS 
[81]. Meanwhile, many FUS fALS-related mutations are localized in the C-
terminal NLS, decreasing the binding affinity between FUS and TNPO1, 
causing mis-localization of FUS to the cytoplasm where it can form inclusions 
that co-localize with stress granule proteins [82-85]. Moreover, a study found 
that patterns of aggregation in nuclear and cytoplasmic FUS are different [86]. 
The study showed that while nuclear FUS requires the QGSY-rich region to 
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form nuclear granules [87], cytoplasmic FUS did not required the prion-like 
domain to form mutant FUS cytoplasmic inclusions, suggesting that the 
structure of these aggregates are different depending on their sub-cellular 
localization. In fact, they showed that the nuclear compartment where FUS 
aggregates are formed, contribute to their distribution pattern and behavior, 
irrespective of WT or mutant FUS. In the same study, the authors found that 
the RNA binding capability of FUS is required to form cytoplasmic inclusions, 
and that chromatin related RNAs are crucial for FUS’ oligomerization [86]. 
Similarly, using a Drosophila model of ALS, a group generated mutants 
deficient in RNA-binding. They found that RNA-binding deficient mutant FUS 
was not able to incorporate into stress granules [88].   Stress granules are 
believed to be a preceding event in inclusion formation, however, further 
studies are necessary to understand how these structures become aberrant 
for the cells, when mutant FUS is present.  
  
1.2.7 FUS and Post-translational modifications 
Post-translational modifications (PTMs) refer to covalent attachments 
or proteolytic cleavages of a functional group to a protein after biosynthesis, 
changing or regulating its subcellular functions and increasing the diversity of 
the proteome [89]. Common eukaryotic PTMs include methylation, 
phosphorylation, acetylation, ubiquitination, and sumoylation (34). Lysine 
acetylation occurs when the acetyl group in acetyl-CoA is transferred to the ε-
amino group of a lysine residue of a protein [90]. This process is reversible, 
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and it is regulated by two types of enzymes: lysine acetyltransferases (HATs), 
that add the acetyl group to the lysine residue, and lysine deacetylases 
(HDACs) that remove it [90].  
Lysine acetylation has many roles in the cells, however the effect of this 
PTM on gene expression has been well characterized. It has been 
demonstrated that when histone tails are acetylated, the interaction between 
the histones and DNA backbone is disrupted, resulting in a relaxation of the 
condensed chromatin, making it more accessible to the transcription 
machinery [91]. However, lysine acetylation can regulate many other functions 
in the cells. A proteomics study identified around 1750 proteins that can be 
acetylated [92]. They also showed that lysine acetylation can be involved in 
various cellular processes including RNA transcription, splicing, DNA damage 
and repair, nuclear transport, and others [92].  
Lysine acetylation has been reported in various neurodegenerative 
disorders, including ALS [93-96]. For example, misfolded tau protein 
acetylation serves as a disease marker for Alzheimer’s pathology [96]. 
Similarly, TDP-43 acetylation impairs RNA-binding and promotes cytoplasmic 
aggregation that resembles the TDP-43 pathology in ALS patients [94]. 
Furthermore, in a yeast study, human FUS was overexpressed, resulting in 
decreased acetylation of histone H3, specifically on lysine 14 (H3K14) and 
lysine 56 (H3K56) [97]. Additionally, these cells showed overall low RNA levels 




In addition, FUS has also been found to interact with histone 
deacetylase 1 (HDAC1) in neurons [98]. This interaction is important for the 
recruitment of HDAC1 to DNA double strand break sites in response to DNA 
damage. Another study found that FUS ΔNLS/ΔNLS knock-in mice showed 
HDAC1 mislocalization to the cytoplasm, suggesting that FUS cellular 
localization affects the function of its interacting partners [98].   
1.2.8 Conclusion and study rationale 
In summary, FUS is ubiquitously expressed in the cells and different 
studies have described its functions in the nucleus and the cytoplasm. On the 
other hand, we also know that lysine acetylation is one of the major PTMs that 
can regulate several functions in the cells. There is evidence by several studies 
that FUS can be modified by arginine methylation regulating the nuclear import 
of FUS, and FUS phase separation [99-101].  However, acetylation of FUS is 
yet to be reported and represents an understudied mechanism in ALS and 
FTLD-FUS pathology. In this study we asked whether FUS is modified by 
acetylation, what sites can be acetylated in FUS, and what are the functional 
consequences of FUS acetylation. The goal of this study is to find new 
regulators of the function of FUS that provide more information on the 
molecular disease mechanism, and to characterize novel targets for 





1.3 Materials and Methods 
1.3.1 Cell culture and transfection 
HEK293Tand N2A cells were cultured in Dulbecco’s Modified Eagle’s 
Medium (Sigma-Aldrich, D5796) with 10% fetal bovine serum, penicillin-
streptomycin, and amphotericin B at 37°C in 5% CO2/95% air with 
humidification. The pCMV10-3×FLAG-FUS WT and pEGFP-C3 FUS plasmids 
were generated as reported [83] FUS mutations were introduced using the 
QuikChange II Site-Directed Mutagenesis Kit (Agilent). HEK293T and N2A 
cells were transfected with Polyethylenimine “Max” (Polysciences, Inc. 24765) 
and Lipofectamine 2000 (Thermo Fisher Scientific, 11668), respectively.  
1.3.2 Immunoprecipitation (IP) 
Cells were lysed with 1× RIPA buffer (Millipore Sigma, 20-188) 
supplemented with protease inhibitor cocktail (Millipore Sigma, P8340, 1:500), 
sodium orthovanadate (1 mM), and deacetylase inhibitor (DACi) cocktail 
(nicotinamide (20 mM), sodium butyrate (20 mM) and Trichostatin-A (1.5 µM)). 
Lysates were homogenized by sonication and centrifuged at 1,000g for 15 
minutes at 4°C. Immunoprecipitations were performed overnight at 4°C using 
EZview™ Red ANTI-FLAG® M2 Affinity Gel (Millipore Sigma, F2426) or 
4µg/ml mouse monoclonal ANTI-FLAG® M2 antibody (Millipore Sigma, 
F3165) and Protein G UltraLink Resin (Thermo Fisher Scientific, 53126). 
Beads were washed three times with lysis buffer and bound proteins were 
eluted with 0.15 µg/µL 3×FLAG peptide (Millipore Sigma, F4799) in 1× RIPA 
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buffer at 4°C for 1 hour. Samples were resolved by SDS-PAGE followed by 
immunoblotting. Where indicated, a cocktail of RNase A and RNase T1 (Life 
Technologies, AM2286) was added to the lysates at 1:100 dilution before the 
overnight immunoprecipitation.  
1.3.3 Immunoblotting 
Proteins resolved by SDS-PAGE were transferred to nitrocellulose 
membranes (Pall, 66485). The membranes were blocked with 5% non-fat dry 
milk in TBST (100 mM Tris-HCl, pH 7.5, 0.9% NaCl, 0.1% Tween-20) or bovine 
serum albumin (BSA) for 1 hour.  The antibodies used include: mouse anti-
FUS (Santa Cruz, sc-47711), mouse monoclonal ANTI-FLAG® M2-
Peroxidase (HRP) (Millipore Sigma, A8592), rabbit anti-acetylated-lysine (Cell 
Signaling Technology, 9441), rabbit anti-PABP1 (Abcam, ab21060), mouse 
anti- β -actin (Santa Cruz Biotechnology, sc-81178), rabbit anti-β-actin (Cell 
Signaling 8457), and a custom-made rabbit anti-K510-acetylated FUS 
antibody (see below).  
1.3.4 Identification of FUS acetylation by Mass Spectrometry 
FLAG-tagged FUS was transfected into HEK293T cells. Transfected 
cells were treated overnight with a cocktail of lysine deacetylase inhibitors (30 
mM nicotinamide, 50 mM sodium butyrate and 3 µM Trichostatin-A) one day 
post-transfection in regular medium. Anti-FLAG immunoprecipitation was 
performed immediately after deacetylase inhibitor treatment. Eluates were run 
on SDS-PAGE and the gel was stained with SYPRO Ruby protein gel stain 
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(Thermo Fisher Scientific, S12000). The bands that corresponded to FLAG-
FUS (electrophoretic mobility of approx. 72 kDa) were excised and subjected 
to dithiothreitol reduction, iodoacetamide alkylation, and in-gel chymotrypsin 
digestion. Peptides were extracted, concentrated and subjected to LC-MS/MS 
analysis at the University of Kentucky Proteomics Core Facility as previously 
reported (48). Briefly, LC-MS/MS analysis was performed using an LTQ-
Orbitrap mass spectrometer (Thermo Fisher Scientific, Waltham, MA) coupled 
with an Eksigent Nanoflex cHiPLC™ system (Eksigent , Dublin, CA) through 
a nano-electrospray ionization source. The peptide samples were separated 
with a reversed phase cHiPLC column (75 μm x 150 mm) at a flow rate of 300 
nL/min. Mobile phase A was water with 0.1% (v/v) formic acid while B was 
acetonitrile with 0.1% (v/v) formic acid. The data-dependent acquisition 
method consisted of an Orbitrap MS scan (300-1800 m/z) with 60,000 
resolution for parent ions followed by MS/MS for fragmentation of the 7 most 
intense multiple charged ions. The LC-MS/MS data were submitted to a local 
MASCOT server for MS/MS protein identification via Proteome Discoverer 
(version 1.3, Thermo Fisher Scientific, Waltham, MA) against a custom 
database containing only RNA-binding protein FUS (FUS_HUMAN) 
downloaded from Uniprot. Typical parameters used in the MASCOT MS/MS 
ion searchinclude: chymotrypsin digestion with a maximum of three missed 
cleavages; 10 ppm precursor ion and 1.2 Da fragment ion mass tolerances; 
lysine acetylation; cysteine carbamidomethylation; methionine oxidation.  
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1.3.5 Generation of FUS KO (∆FUS) N2A cells.  
The FUS knockout cells were generated by employing CRISPR 
technology. N2A cells were transfected with FUS double nickase CRISPR 
plasmid (Santa Cruz Biotechnology, sc-433326-NIC) following the 
manufacturer’s instructions. Clonal cell lines were isolated with serial dilution, 
and the FUS status of the clones was determined with immunoblotting. 
1.3.6 Generation of the anti-acetylated-K510 FUS antibody. 
All peptides below were synthesized with an added extra N-terminal 
cysteine residue to facilitate conjugation to Sulfolink resin or KLH (Genscript, 
Piscataway, NJ). The rabbit anti-acetylated-K510 FUS antibody was raised 
against the peptide antigen N-G504GFGPG(K510Ac)MDSRG515-C. The 
peptide was synthesized with C-terminal amidation and conjugated to Keyhole 
Limpet Hemocyanin (KLH) for immunization (Pocono Rabbit Farm and 
Laboratory, Canadensis, PA). The serum was first depleted with the non-
acetylated FUS peptide N-G504GFGPGK510MDSRGEHRQDRRERPY526-
C, then affinity-purified with the acetylated FUS peptide N-
G504GFGPG(K510Ac)MDSRGEHRQDRRERPY526-C conjugated to 
Sulfolink resin (Thermo Fisher Scientific, 44999). The antibodies were eluted 
with 0.1 M glycine-HCl buffer, pH 2.5, neutralized by the addition of Tris-HCl, 
1 M, pH 8.5, and dialyzed against storage buffer (50 mM Tris-HCl, pH 7.5, 150 
mM NaCl, 10% glycerol, 0.04% [w/v] sodium azide). 
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1.3.7 GST-TNPO1 purification 
The human TNPO1 coding region was PCR amplified with primers 5’-
CGTCGGATCCATGGAGTATGAGTGGAAACCT-3’ and 5’-
CGTCGTCGACTTAAACACCATAAAAAGCTGCAAGA-3’ from MGC clone 
4178989 as template and inserted between the BamHI and SalI sites of pGEX-
6P-3 (GE Healthcare 28-9546-51). The GST-TNPO1 fusion protein was 
expressed in Rosetta 2 (DE3) pLysS E. coli cells (Millipore 71401) at 28°C 
incubation temperature, purified using Glutathione Sepharose 4B resin (GE 
Life Sciences, 17-0756-01) following the manufacturer’s recommendations, 
and eluted with 15 mM reduced L-glutathione (Gold Biotechnology, G-155-25) 
in 100 mM Tris-HCl, pH 8.0, and 2 mM DTT. Aliquots were flash-frozen in liquid 
nitrogen and stored at −80°C until use. 
1.3.8 GST-TNPO1 pulldown with Sulfolink-immobilized FUS peptides 
The acetylated and non-acetylated FUS peptides synthesized with an 
added extra N-terminal cysteine residue were immobilized to Sulfolink resin 
following the manufacturer’s instructions (Thermo Fisher Scientific, 44999). 
The beads were blocked with 0.5mg/mL BSA in TNPO1 buffer (20mM Na-
PO4, pH7.4, 150mM KCl, 0.5mM EDTA, 5mM MgCl2, 10% glycerol, 1mM 
DTT, 20mM Nicotinamide) for 1h at 4°C. The indicated amounts of GST-
TNPO1 were added to the blocked beads with the immobilized FUS peptides 
and incubated at 4°C for 3 hours with mild rotation. The beads were washed 
with TNPO1 buffer 3 times and eluted by the addition of 2× Laemmli sample 
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buffer with beta-mercaptoethanol. After incubation at 94°C for 5 minutes, the 
eluted samples were subjected to SDS-PAGE and Western blot.  
1.3.9 Immunoprecipitation followed by qPCR 
Immunoprecipitation was carried out as described above, with the 
difference that SUPERase-In RNase Inhibitor (Thermo Fisher Scientific, 
AM2696, 0.2 U/µl) was added to the lysis and elution buffers, and incubation 
with the antibody was performed for 2 hours. In the last step of the 
immunoprecipitation, the eluted sample was divided into two aliquots. One 
aliquot was used for immunoblotting and the other was used for RNA isolation 
using TRIzol Reagent (Thermo Fisher Scientific, 15596), following the 
manufacturer’s instructions. Equal aliquots of the isolated RNA were reverse 
transcribed using the SuperScript III First-Strand Synthesis System (Thermo 
Fisher Scientific, 18080). The resulting cDNA was subjected to quantitative 
real-time PCR using Power SYBR Green PCR Master Mix (Thermo Fisher 
Scientific, 4367659). The qPCR primers and annealing temperatures were: 
mouse FUS pre-mRNA flanking exon 7, 5’-CAACCCTTTTGTAGCCGTTGG-
3’ and 5’-CAGCAGGAGGCATTCTACCC-3’, 59°C; and mouse RPL13A, 5’-
CTGTGAAGGCATCAACATTTCTG-3’ and 5’-
GACCACCATCCGCTTTTTCTT-3’ [102], 55°C. The qPCR results were 
analyzed using the ∆∆CT method. 
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1.3.10 Immunofluorescence and fluorescence microscopy  
N2A cells were seeded on gelatin-treated coverglass and transfected 
with EGFP-FUS constructs. Cells were treated with the lysine deacetylase 
inhibitor cocktail for six hours when indicated. 48h after transfection, cells were 
fixed with 4% formaldehyde in 1× PBS (137 mM NaCl, 2.7 mM KCl, 10 mM 
Na2HPO4, 2 mM KH2PO4, pH 7.4), and permeabilized with 1× PBS 
supplemented with 0.25% [v/v] Triton-X100. The coverslips were blocked with 
10% [w/v] BSA in 1× PBS for 1h, followed by incubation with primary antibody 
at room temperature overnight. Coverslips were rinsed with 1× PBS and 
incubated with secondary antibodies for 1 hour at 37°C. The primary antibody 
was rabbit anti-G3BP1 (Proteintech, 13057-2-AP) and the secondary antibody 
was Alexa Fluor 568 donkey anti-rabbit (Thermo Fisher Scientific, A10042). All 
the samples were stained with 4′,6-Diamidino-2-phenylindole (DAPI) and 
mounted with Vectashield Mounting Medium (Vector Laboratories, H-1000-
10). Confocal images were acquired using a Nikon A1 confocal microscope 
with a 40x objective. Z-stack images were obtained from random view fields 
using identical parameters for all the samples. Maximum intensity projections 
of the Z-stacks were analyzed using ImageJ (http://imagej.nih.gov/ij) as 
reported previously [103].  Inclusion-positive cells were defined as any cell with 
one or more inclusions larger than 5 pixels. The number of inclusion-positive 




1.3.11 Patient skin fibroblast isolation and culture 
Human skin fibroblasts were prepared and maintained as described 
(78). ALS patients and healthy family members consented to donate the 
samples. Protocol was reviewed and approved by the Institutional Review 
Board of the University of Kentucky. A skin biopsy of 3 mm diameter was 
obtained from the subjects and the tissue was washed in phosphate-buffered 
saline (PBS), minced, and incubated in Minimum Essential Medum (Sigma-
Aldrich, M5650) supplemented with 20% FBS, 2 mM L-glutamine, 100 unit/mL 
penicillin, and 100 μg/mL streptomycin) at 37°C under 5%CO2/95% air. 
Information on the subjects examined in this study is shown in Table 1.1 
1.3.12 Statistical analysis 
The quantification of Western blot bands was performed using Image 
Lab software by BioRad. Statistical analysis was performed with SigmaPlot 
14.0 software. Band intensities were calculated and comparison between 
groups was performed using Anova with post hoc Tuckey HSD test. Student’s 
t test was used to determine statistical significance between two groups. Chi 
square was used to compare difference between proportions. Experiments 
were not blinded. Fluorescence microscopy was quantified from more than 10 













ID Group FUS 
genotype 
Gender Age of 
sample 
collection  
017 Control WT/WT Female 43 
010 Control WT/WT Female 36 
012 Control WT/WT Female 63 
008 Control WT/WT Female 24 
089 Control WT/WT Male 20 
091 ALS patient WT/R521G Female 31 
014 ALS patient WT/R521G Male 42 
007 ALS patient WT/R521G Male 58 
018 ALS patient WT/R521G Female 40 
090 ALS patient WT/P525R Female 26 
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1.4 Results  
1.4.1 FUS is acetylated at specific lysine residues in two distinct functional 
domains. 
To evaluate whether FUS was acetylated, we immunoprecipitated 
endogenous FUS from N2A cells treated with a deacetylase inhibitor (DACi) 
cocktail (30 mM nicotinamide, 50 mM sodium butyrate and 3 µM Trichostatin-
A), followed by immunobloting with a pan-acetylated lysine antibody. A 
prominent acetylated FUS band was observed in the presence of DACi cocktail 
as compared to a significantly weaker band in the absence of DACi (Figure 
1.2A). The result suggests that FUS is acetylated and the acetylation is 
dynamic. 
Next, we used LC-MS/MS to identify the lysine acetylation sites. 
3×FLAG-tagged FUS was transfected into HEK293T cells and treated with the 
DACi cocktail overnight. Subsequently, a FLAG immunoprecipitation (FLAG-
IP) was performed, and the eluates were run on SDS-PAGE followed by 
SYPRO Ruby staining. FUS bands at approximately 72 kDa were excised, 
subjected to in-gel chymotrypsin digestion, and analyzed by liquid 
chromatography tandem mass spectrometry (LC-MS/MS) as previously 
described [104]. Figure 1.2B shows the mass spectrometric evidence of FUS 




We next validated these three acetylation sites using a mutagenesis 
approach, in which acetylation mimicking mutants (Lys to Gln or K/Q) were 
generated for each site. Mutating lysine to glutamine is a method widely used 
in the field to study protein acetylation [94, 104]  In our data, replacing lysine 
with glutamine at K315 or K316 alone did not result in significant loss of FUS 
acetylation (Figure 1.2D-E). However, when these two sites were mutated 
together, FUS acetylation was decreased significantly (Figure 1.2D-G). This 
suggests that acetylation at both sites may occur interchangeably, which is 
consistent with the detection of di-acetylation of K315 and K316 in the LC-
MS/MS analysis. Similarly, K510Q mutant decreased FUS acetylation 
significantly, and mutating the three sites also showed acetylation decrease 
(Figure 1.2F-G). FUS lysine acetylation was not completely abrogated in the 
triple K315/316/510Q mutant, suggesting that additional acetylation sites 
might be present beyond the detection limit in our study.  
Lysine residues 315 and 316 are localized in the RNA recognition motif 
(RRM), specifically in the very positively charged KK-loop that facilitates the 
electrostatic interaction between FUS and DNA/RNA (Figure 1.2H). NMR 
structure of the RRM domain found that K315 and K316 are inserted into the 
major groove of the stem-loop RNA and in contact with the ribose-phosphate 
backbone of both strands [105]. Previous studies have shown that replacing 
lysine residues by alanine in the KK-loop disrupted nucleic acid binding [57]. 
Thus, we hypothesized that acetylation of K315/K316 could regulate the RNA 
binding of FUS by a similar mechanism (Figure 1.2I). In contrast, lysine 510 is 
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localized in the C-terminal NLS (Figure 1.2J). The NLS of FUS interacts with 
the nuclear transport receptor Transportin-1 (TNPO1) at multiple positively 
charged residues including K510, and this interaction is crucial for nuclear 
localization and function of FUS [81, 85]. Our hypothesis was that acetylation 
at K510 disrupts the interaction between FUS and D693 of TNPO1 (Figure 
1.2J) by removing the positive charge of lysine and imposing steric hindrance. 
The net effect was predicted to be that K510 acetylation affects the interaction 
with TNPO1 and thereby regulates the subcellular localization of FUS. 
 
1.4.2 Acetylation of FUS at K315/K316 regulates its RNA binding activity.  
To test the hypothesis that acetylation of K315/K316 regulates RNA 
binding to FUS, we first tested FUS binding to its own pre-mRNA surrounding 
exon 7 as previously reported [72]. The 3×FLAG-tagged FUS (WT and K-Q 
acetylation mimicking mutants) was immunoprecipitated and the quantity of 
FUS pre-mRNA was measured by reverse transcription and quantitative PCR. 
The K315/316Q acetylation mimicking mutant co-precipitated significantly less 
FUS mRNA as compared to WT FUS (Figure 1.3A). In contrast, K510Q did 
not change the RNA binding. As a control, we verified that the total FUS pre-
mRNA levels were comparable in all cell extracts (Figure 1.3A). 
A second assay was used to test FUS RNA binding by examining the 
interaction between FUS and poly-A binding protein (PABP1), which was 
reported to be RNA-dependent [83]. We performed a FLAG-IP from N2A cells 
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transfected with 3×FLAG-tagged WT or K/Q mutant FUS to examine the FUS-
PABP1 interaction. As expected, in the presence of RNase cocktail containing 
a mixture of RNAse A and RNASe T1, the WT FUS-PABP1 interaction was 
completely abrogated (Figure 1.3B-C). When the cells were treated with DACi 
cocktail, the WT FUS-PABP1 interaction decreased significantly, suggesting 
that acetylation affected RNA binding. We also found that the PABP1-FUS 
interaction was affected even by single K/Q mutations in the KK-loop, and 
when both sites were mutated to glutamine, the interaction was impaired at 
similar levels as the DACi treatment itself (Figure 1.3B-C).  In contrast, K510Q 
mutant did not affect the FUS-PABP1 interaction. Overall, these results 
support the hypothesis that lysine acetylation of K315/K316 impairs FUS 
binding to RNA. 
 
1.4.3 The effect of FUS K510 acetylation on the FUS NLS-TNPO1 interaction. 
To test the hypothesis that acetylation of K510 affects the interaction 
between FUS and TNPO1 and influences the subcellular localization of FUS, 
we employed chemically synthesized FUS-NLS containing the acetylated 
K510 in an in vitro interaction study with TNPO1. The acetylated and non-
acetylated FUS-NLS peptides were immobilized to Sulfolink resin and 
incubated with different amounts of purified GST-TNPO1. The pulldown of 
TNPO1 by the non-acetylated FUS peptide was detectable with the lowest 
amount of 12.5 pmol TNPO1 (Figure 1.3D). However, the K510-acetylated 
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FUS-NLS peptide pulled down significantly less TNPO1 noting that the 
interaction was almost undetectable with 25 pmol of TNPO1 (Figure 1.3D-E). 
As a control, Sulfolink beads without FUS peptide were subjected to the same 
immobilization protocol and incubated with 0 or 200 pmol of TNPO1. No signal 
was detected at 0 pmol of TNPO1 but a weak band was detected when 200 
pmol of TNPO1 was incubated with the blank beads. Thus, acetylation of K510 
affected the interaction between FUS and TNPO1, suggesting that this post-
translational modification in the NLS reduces the nuclear import of FUS and 
hence may alter cytoplasmic localization. 
 
1.4.4 Acetylation of FUS at distinct sites differentially alter cellular localization and 
stress granule formation. 
Since the acetylation at K315/K316 and K510 residues affects the FUS-
RNA and the FUS-TNPO1 interaction, respectively, we used acetylation mimic 
K/Q mutants to determine whether acetylation of these lysine residues 
differentially affect its subcellular localization and inclusion formation by 
fluorescence microscopy. In Figure 1.4A, EGFP-tagged WT FUS was 
localized to the nuclei of N2A cells. Similarly, the K315Q/K316Q mutant was 
localized to the nuclei of the cells, suggesting that acetylation of K315/K316 
residues did not affect FUS nuclear localization. In contrast, ~30% of the 
K510Q mutant showed cytoplasmic localization while ~40% of the triple K/Q 
mutant FUS was in the cytoplasm (Figure 1.4A-B). More interestingly, ~59% 
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of cells expressing the K510Q mutant FUS showed cytoplasmic inclusions 
whereas only ~22% of cells expressing the triple mutant 
K315Q/K316Q/K510Q showed cytoplasmic inclusions (Figure 1.4C, p<0.001). 
The reduced formation of cytoplasmic inclusions by the triple K/Q mutant 
suggests that that RNA binding is important for the formation of FUS 
cytoplasmic inclusions, which is consistent with our previous report [106]. 
Next, we assessed whether the cytoplasmic inclusions formed by acetylation 
mimicking mutants were colocalized with the stress granule marker G3BP1 in 
N2A cells using fluorescence microscopy. As expected, EGFP-FUS WT and 
K315Q/316Q neither formed inclusions nor co-localized with G3BP1. In 
contrast, EGFP-FUS K510Q and K315Q/K316Q/K510Q cytoplasmic 
inclusions were co-localized with G3BP1 (Figure 1.5). These results are 
consistent with previous studies that ALS mutant FUS forms cytoplasmic 
inclusions co-localized with stress granule markers [83, 86]. Taken together, 
we conclude that the acetylation of K510 affects the interaction between FUS 
and TNPO1, causing the mis-localization of FUS to the cytoplasm and the 
formation of stress granule-like inclusions. In addition, the acetylation of 





1.4.5 FUS acetylation in the RRM domain decreases the formation of ALS mutant 
inclusions. 
To further test whether acetylation of K315/K316 in the KK-loop of the 
RRM domain affects the formation of FUS cytoplasmic inclusions by disrupting 
RNA binding, we transfected N2A cells with the EGFP-tagged FUS ALS 
mutant P525L with or without harboring the acetylation mimicking mutation 
K315Q/K316Q. The P525L mutation itself caused mis-localization to the 
cytoplasm as previously reported [107] and ~48% of the P525L mutant-
expressing cells showed cytoplasmic inclusions (Figure 1.4D-E). However, 
only ~11% of cells expressing the P525L/K315Q/K316Q mutant FUS showed 
cytoplasmic inclusions (Figure 1.4D-E, p<0.001). Furthermore, cells 
expressing EGFP-P525L FUS were treated with the DACi cocktail and the 
percentage of cells with cytoplasmic inclusions decreased from ~33% in the 
absence of DACi to ~5% in the presence of DACi (Figure 1.4F-G, p<0.001). 
Thus, the results support that the acetylation of the K315/K316 residues 
reduces the ability of ALS mutants of FUS to form cytoplasmic inclusions 
 
1.4.6 K510 acetylation is increased in FUS ALS patients 
Since the K510 acetylation mimicking mutant significantly increased 
cytoplasmic mis-localization and inclusion formation (Figure 1.4A-C), we 
examined the status of K510 acetylation in ALS patients. We first generated a 
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site-specific antibody against acetylated K510. The rabbit polyclonal antibody 
specifically detected hyper-acetylated FUS in human HEK293T cells and 
mouse N2A cells in the presence of DACi, but did not detect any signal in FUS-
null N2A cells (Figure 1.6A). Additionally, we transfected FUS-null N2A cells 
with either empty vector, or WT, K510Q, or K510R FUS with or without DACi 
cocktail. The antibody detected a strong band in extracts from WT FUS-
expressing cells treated with DACi, whereas it did not detect any signal in 
K510R mutant extract treated with DACi (Figure 1.6B). The acetylation 
mimicking mutant K510Q produced a very faint band, thus, the antibody is 
specific for FUS acetylation of K510. We used this acetyl-K510 specific 
antibody to analyze human skin fibroblast samples from FUS ALS patients and 
healthy controls. Levels of K510 acetylation were normalized against total 
FUS. We found ∼50% increased levels of acetylated FUS K510 in ALS 
patients (p = 0.015) (Figure 1.7A-B). These results suggest that acetylation of 
FUS could be associated with pathological characteristics of FUS ALS. 
 
1.4.7 FUS is acetylated by CBP/p300  
The CREB-binding protein (CBP) and p300 form a select family of lysine 
acetyltransferases (KATs) due to their structural and functional similarities 
[108, 109]. These proteins are responsible for a large portion of the acetylation 
of histone and non-histone proteins in mammalian cells [109]. FUS has been 
shown to interact with CBP/p300 [39], and to verify that CBP/p300 acetylates 
FUS we co-transfected HA-tagged CBP and FLAG-tagged FUS into N2A cells. 
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After FLAG immunoprecipitation, pan-acetylated lysine antibody showed a 
strong signal when HA-CBP was present compared to HA-empty vector 
(Figure 1.8A), indicating that FUS was acetylated by CBP/p300.  
 We then treated N2A cells with DACi cocktail plus compound A-485, a 
highly selective CBP/p300 inhibitor [110], at different concentrations for 24h. 
We detected a significant signal decrease in acetylated-K510 FUS with 
increasing concentrations of A-485 (Figure 1.8B-C). Interestingly, treatment of 
8 µM A-485 did not change the total acetylation as detected by the pan-
acetylated lysine antibody while K510 acetylation significantly decreased 
(Figure 1.8D). The results suggest that endogenous CBP/p300 is a major 
acetyltransferase at the K510 site of FUS.  
 
1.4.8 FUS is deacetylated by HDAC and Sirtuins lysine deacetylases  
Lysine deacetylases are enzymes that play an important role in 
regulating epigenetic changes that are critical for gene expression. They are 
classified into different families: HDACs are Zn2+-dependent lysine 
deacetylases while Sirtuins require nicotinamide adenine dinucleotide (NAD+) 
[111]. To identify which family of lysine deacetylases deacetylate FUS, we 
treated N2A cells with two deacetylase inhibitors for 24h: nicotinamide which 
inhibits sirtuins [112], and Trichostatin-A (TSA) which inhibits a broad range of 
HDACs [113]. We first examined the total acetylation by FLAG 
immunoprecipitation followed by Western blot using a pan-acetylated lysine 
antibody (Figure 1.8E-F). Cells treated with nicotinamide showed a trend of 
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increase without statistical significance. Cells treated with TSA showed a 
significant increase of total FUS acetylation. Cells with both nicotinamide and 
TSA showed ~8x increase of total FUS acetylation as compared to the control 
(Figure 1.8E-F). Next, we evaluated the effect of these inhibitors on the K510 
site. In cells treated with nicotinamide or TSA alone, we observed a significant 
increase in FUS-K510 acetylation compared to the vehicle control. In the same 
fashion, treating with both nicotinamide and TSA together, we detected a ~15x 
increase in FUS-K510 acetylation (Figure 1.8G-H).  This suggests that both 
HDACs and Sirtuins are able to deacetylate FUS.  
We next used co-precipitation assays to identify candidate FUS lysine 
deacetylases. A set of FLAG-tagged expression constructs for all known 
human lysine deacetylases (HDACs 1-11 and SIRTs 1-7) were transfected into 
HEK293T cells, followed by endogenous FUS immunoprecipitation. Among 
the 11 HDACs and 7 SIRTs (Figure 1.9A-B) tested, only HDAC3 and SIRT7 
co-precipitated with the endogenous FUS (Figure 1.8I), suggesting that these 
lysine deacetylases might be involved in FUS deacetylation. SIRT6 and 
hnRNPA1 were included as a negative and positive control in the co-
precipitation study, respectively (Figure 1.8I). The results in Figure 1.8I are 
consistent with the results in Figure 1.8E-H that the FUS acetylation level 
increased in the presence of either HDAC or SIRT inhibitors.  
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1.5 Discussion  
FUS is a DNA/RNA binding protein that belongs to the FET/TET family 
of proteins, including TAF15 and EWS. FUS mutations have been linked to 
familial ALS [29] and FUS pathology is also found in a subset of FTD [114]. 
FUS is a ubiquitously expressed protein that has many molecular functions in 
the cell. In this study, we found that the biochemical properties of FUS are 
modulated by acetylation. First, using a mass spectrometry approach, we 
identified lysine acetylation sites in the RRM domain and C-terminal NLS of 
FUS. Lysine residues 315 and 316 are located in the KK-loop, which is a 
structural component of the RRM domain and is involved directly in DNA and 
RNA binding [57]. The lysine residue 510 is located in the NLS of FUS, a 
domain that is primarily responsible for importing FUS into the nucleus. 
Remarkably, mutations in this site (K510E, K510R and K510M) have been 
reported in familial ALS cases [115-117]. These findings led us to hypothesize 
that acetylation of lysine at these sites could influence the biochemical function 
of FUS in the cell. 
FUS-NLS domain harbors most of the reported ALS mutations, 
resulting in aberrant FUS protein mis-localization and aggregation in the 
cytoplasm [82-85]. The interaction between FUS-NLS and TNPO1 is critical 
for importing FUS into the nucleus. Structural analysis showed that the 
positively charged K510 residue interacts with the negatively charged D693 
residue of TNPO1 (Figure 1.2J) [81]. It is conceivable that the addition of an 
acetyl group to K510 could disrupt the interaction between K510 and D693. In 
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addition, the acetyl group can also cause steric hindrance between the K510 
and D693 residues. Thus, K510 acetylation would reduce FUS binding affinity 
to TNPO1 and increase the cytoplasmic localization of FUS. It was reported 
that familial ALS patients with the K510R mutation manifest a mild phenotype 
and long survival after disease onset [117]. Although both arginine and lysine 
contain positively charged side chains, the Arg side chain is spatially larger 
than Lys, consistent with the notion that the K510R mutation may disrupt the 
FUS NLS-TNPO1 interaction to a lesser degree, accounting for mild disease 
phenotypes. In contrast, FUS K510E ALS patients showed early onset and 
rapid progression of the disease supporting the concept that a negative charge 
at position 510 is particularly deleterious [118]. Our previous data showed that 
K510E has only 1% binding affinity to TNPO1 [81], and it has been shown that 
a severe disruption of nuclear import could be correlated with a rapid 
progression of the disease [119]. These results suggest that FUS NLS is 
sensitive to perturbations at the K510 residue, including mutations or post-
translational modifications like acetylation discovered in this study. Indeed, our 
results showed that FUS acetylation at K510 disrupted the interaction with 
TNPO1 (Figure 1.3D-E), leading to the cytoplasmic accumulation of FUS and 
the formation of G3BP1-positive stress granule-like inclusions in the cytoplasm 
(Figure 1.4A-C, Figure 1.5). Several transgenic mice models have shown that 
cytoplasmic aggregation and inclusion formation contribute to 




FUS-RRM domain has been reported to bind various nucleic acids, 
ranging from DNA to G-quadruplex RNA [57]. The K315/K316 motif in FUS-
RRM domain exhibits tandem positive charges at the protruding tip of the KK 
loop and contributes significantly to the electrostatic interaction with the 
negatively charged nucleic acids. Point mutations K315A/K316A abolished 
FUS nucleic acid binding [57]. Similarly, our results show that acetylation 
mimicking mutations in the KK-loop significantly reduce the RNA binding 
capability of FUS (Figure 1.3A-C), most likely by neutralizing the positive 
charge of lysine, leading to a decreased affinity to the negatively charged 
backbone of the nucleic acids [123]. Finally, the attachment of an acetyl group 
to lysine could cause a steric clash with its interaction partners.  
An interesting observation from our immunofluorescence experiments 
was that transfecting the cells with EGFP-K315Q/K316Q/K510Q caused FUS 
to mis-localize to the cytoplasm, but the percentage of cells with cytoplasmic 
inclusions decreased significantly when compared to EGFP-K510Q (Figure 
1.4C). These results are in agreement with our previous study that FUS-RNA 
binding is required for the formation of cytoplasmic inclusions [86]. That study 
demonstrated that when FUS RNA binding domains were truncated, the 
formation of inclusions significantly decreased as compared to the R495X FUS 
ALS mutant. Other work showed that mutating K315 and K316 to Ala residues 
prevented the formation of cytoplasmic inclusions by the R495X mutant [57]. 
These data are consistent with the results obtained in this study that 
introducing the acetylation mimics at the RNA-binding sites into the ALS 
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mutant P525L (P525L/K315Q/K316Q) significantly reduced the percentage of 
cells with cytoplasmic inclusions as compared to the P525L mutation alone 
(Figure 1.4D-E). Consistent with these findings, we showed that treating cells 
expressing the P525L ALS mutant with deacetylase inhibitor cocktail 
significantly reduced the percentage of cells with cytoplasmic inclusions 
(Figure1.4F-G). Our results are relevant to a recent study showing that 
dynamic multi-valent interaction between FUS and RNA is critical to 
maintaining the fluidity and function of FUS [124].  FUS mutations that 
constrain the FUS-RNA interactions lead to higher order complex of 
ribonucleoprotein aggregates [124]. Finally, RNA binding was also shown to 
play a critical role in the formation of stress granules and pathological inclusion 
of TDP-43 [125]. These studies support our conclusion that RNA binding is 
critical for self-assembly of FUS into cytoplasmic inclusions and that Lys 
acetylation in the RRM domain can effectively modulate RNA binding and 
inclusion formation of mutant FUS.  
To identify the lysine deacetylases that might regulate FUS acetylation, 
we first used nicotinamide and TSA to test whether FUS acetylation is 
susceptible to Sirtuins or HDACs, respectively. Our results showed that total 
FUS acetylation as well as FUS K510 acetylation can be mediated by both 
Sirtuins and HDACs (Figure 1.8E-H). It is noted that the effect of nicotinamide 
alone on the total acetylation level was not statistically significant. It has been 
reported that the expected inhibitory effect of nicotinamide could be unreliable, 
in particular, nicotinamide was reported to stimulate the SIRT1 activity [126]. 
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We next examined which specific Sirtuin or HDAC interacted with FUS using 
immunoprecipitation. We found that SIRT7 and HDAC3 interact with FUS. The 
FUS-SIRT7 interaction was previously reported in a proteomics study [127] but 
was not experimentally validated. SIRT7 is a NAD+-dependent deacetylase 
that acts on histone and non-histone proteins [128]  and it is localized in the 
nucleus, but primarily in the nucleolus [129]. Moreover, we identified a novel 
interaction between HDAC3 and FUS. HDAC3 is a Zn2+-dependent class-I 
HDAC that has been reported to shuttle between the nucleus and the 
cytoplasm [130]. An interaction between FUS and HDAC1 was reported 
previously [38], however we could not confirm this interaction under our 
experimental conditions. Future studies of genetically reducing HDAC3 and 
SIRT7 are needed to confirm that they indeed deacetylate FUS.  
We also demonstrated that endogenous CBP/p300 is a major 
acetyltransferase for FUS, particularly the K510 site (Figure 1.8A-D). The 
CBP/p300 inhibitor A-485 [110] significantly decreased FUS K510 acetylation 
in a dose-dependent manner in N2A cells (Figure 1.8B-C), however the total 
FUS acetylation did not show significant change, suggesting that the 
acetylation of the specific K510 site is more sensitive to CBP/p300 inhibitor. 
Reports show that CBP/p300 is localized to the nucleus [131] and is 
responsible for acetylation of over two-thirds of the lysine acetylation sites. 
Overall, the process of FUS acetylation/deacetylation appears to be very 
dynamic, and it is likely that other acetyltransferase enzymes play a role in 
FUS acetylation at other sites such as K315/K316. The functional 
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consequence of inhibiting the specific acetyltransferases (e.g. CBP/p300) and 
deacetylases (e.g. SIRT7 and HDAC3) on the subcellular localization and 
inclusion formation of FUS remains to be determined in future studies.  
To our knowledge, lysine acetylation of human FUS has not been 
reported previously. A proteomics study reported the acetylation of K502 in rat 
FUS and K640 in rat EWS, the equivalent of K510 in human FUS. The 
acetylation of the K263 residue in rat TAF15 was also reported, which 
corresponds to K316 in human FUS [132]. Although the acetylation of those 
residues was not further validated and their functional relevance was not 
studied, the proteomic identification of acetylation of these conserved residues 
in the FET family proteins across species is supportive of the importance of 
our findings demonstrating acetylation of K315, K316 and K510 residues. Our 
mutagenesis and pharmacological studies demonstrate that acetylation of 
these residues bestowed a profound impact on FUS subcellular localization as 
well as the formation of stress granule-like cytoplasmic inclusions.  
More interestingly, a higher K510 acetylation level was observed in 
familial FUS ALS patients as compared to healthy controls (Figure 1.7A-B), 
suggesting that acetylation could play a role in disease pathogenesis and/or 
serve as a molecular hallmark of the disease. Particularly, K510 acetylation 
increased the cytoplasmic inclusions (Figure 1.4A-C). Based on all results in 
this study, a working model is proposed to illustrate the role of FUS acetylation 
(Figure 1.10). Acetylation of K315/K316 disrupts the RNA binding but does not 
interfere with the TNPO1-mediated nuclear import of FUS. In contrast, 
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acetylation of K510 disrupts the interaction with TNPO1 and promotes the 
formation of cytoplasmic inclusions. When all three lysine residues are 
acetylated, FUS accumulates in the cytoplasm but forms less inclusions due 
to impaired RNA binding. We propose this process to be dynamic and the three 
forms of FUS acetylation can be present simultaneously. For ALS-linked 
mutations, mutant FUS shows reduced TNPO1 binding, impaired nuclear 
import, and cytoplasmic accumulation. Moreover, mutant FUS shows a higher 
level of K510 acetylation in ALS patients, facilitating the formation of 
cytoplasmic inclusions. Future studies are needed to test whether CBP/p300 
inhibitors can mitigate mutant FUS mediated disease pathology by 
suppressing the K510 acetylation.   
The pathologic inclusions are a clinical characteristic of mutant FUS 
mediated ALS/FTD. Studies show that different types of stress granules can 
form in a G3BP1-dependent [133] or independent [134] fashion, and can 
generate different functional outcomes [135]. The role of acetylation of FUS in 
stress granules and the functional consequence of such acetylation-
dependent granules remains to be determined in future studies. In addition, a 
recent study reported that nuclear-to-cytoplasmic mis-localization of FUS 
without aggregation in the cytoplasm occurred in different models of FUS ALS 
[136]. We propose that pharmacologically modulating acetylation of FUS can 
prevent protein mis-localization or formation of pathological inclusions, 
providing new targets for therapeutic treatments against FUS-mediated 




Figure 1.1 The functional domains of FUS  
 
QGSY-rich, Glutamine/Glycine/Serine/Tyrosine rich domain; G, Glycine 
rich domain; RGG, Arginine/Glycine/Glycine rich domain; E, Nuclear export 




















(A) Endogenous FUS immunoprecipitation from N2A cells treated with 
deacetylase inhibitor cocktail (DACi) (nicotinamide (30 mM), sodium butyrate 
(50 mM) and Trichostatin-A (3 µM)) for 6h. Immunoblotting was performed 
using the indicated antibodies. (B) Mass spectrometric identification of the 
acetylated FUS peptide 
RGGRGGGDRGGFGPGK510MDSRGEHRQDRRERPY. (C) The MS/MS 
spectrum of the di-acetylated peptide 
305FKQIGIIKTNKKTGQPMINLYTDRETGKL333. The series of matched b and y 
ions are shown in blue and red, respectively. The b11, b12, y18 and y19 ions 
supporting the K315 and K316 acetylation sites are labeled in bold. (D) 
3×FLAG-tagged WT, K315, K316Q, K315Q/K316Q or FLAG vector control 
were transfected into N2A cells. After 24h, cells were treated with deacetylase 
inhibitor cocktail for 6h, followed by FLAG immunoprecipitation and 
immunoblotting with the indicated antibodies. (E) Quantification of FUS 
acetylation from three independent experiments ± SD. Student’s t-test was 
performed for individual comparisons against WT. *, p ≤0.05.  (F) 3×FLAG-
tagged WT, K315Q/K316Q, K510Q, K315Q/K316Q/K510Q or FLAG vector 
control were transfected into HEK293T cells. After 24h, cells were treated with 
deacetylase inhibitor cocktail for 6h, followed by FLAG immunoprecipitation 
and immunoblotting with the indicated antibodies. (G) Quantification of FUS 
acetylation from three independent experiments ± SD. Student’s t-test was 
performed for individual comparisons against WT. *, p ≤0.05.  (H) The domain 
structure of FUS showing the RRM domain sequence and acetylation sites. (I) 
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NMR solution structure of FUS RRM domain (pink) showing K315 and K316 
in the KK-loop bound to stem-loop RNA (Protein Data Bank entry 6GBM). (J) 
Crystal structure of TNPO1/FUS-NLS (Protein Data Bank entry 4FQ3) 
illustrating the FUS-NLS domain (pink) K510 adjacent to TNPO1 (purple) 

















Figure 1.3. Acetylation of FUS impairs RNA binding and the FUS NLS-TNPO1 
interaction 
 
(A) 3×FLAG-tagged FUS constructs were transfected into N2A cells. 
After 48h, cells were lysed, and FLAG-IP followed by reverse transcription and 
quantitative PCR against FUS pre-mRNA surrounding exon 7 was performed. 
FUS mRNA was normalized with the FLAG levels in the FLAG-FUS 
immunoprecipitations and with the Rpl13a mRNA levels in the total extracts. 
Averages of three independent experiments are shown, ± SD. Student’s t-test 
was performed for individual comparisons against WT. (B) The indicated 
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3×FLAG-tagged FUS constructs were transfected into N2A cells and treated 
with DACi cocktail where indicated. FLAG immunoprecipitation was performed 
48h after transfection with the inclusion of RNase cocktail as indicated, 
followed by immunoblotting with the indicated antibodies. (C) Quantification of 
(B) from three independent experiments. Student’s t-test was performed for 
individual comparisons against WT. Significance:  *, p ≤0.05; **, p≤0.005; ***, 
p ≤0.001; n.s: not significant.  (D) In vitro TNPO1 pulldown with Sulfolink-
immobilized acetylated or non-acetylated FUS-NLS peptides. Different 
amounts of GST-TNPO1 were incubated with FUS-NLS peptide immobilized 
on the beads at 4°C for 3 hours. The amount of TNPO1 pulled down with FUS-
NLS peptides were evaluated by Western blot. (E) Quantification of (D) from 
three independent experiments, ± SD. Student’s t-test was performed 
comparing the band intensities of non-acetylated and acetylated peptide 
pulldowns at the same concentration. Significance:  *, p ≤0.05; **, p≤0.005; ***, 








Figure 1.4. The effect of FUS acetylation on cellular localization and stress 
granule formation. 
 
(A) N2A cells were transfected with EGFP-tagged WT, K315Q/K316Q, 
K510Q and K315Q/K316Q/K510Q FUS. The nuclei were visualized with DAPI. 
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Samples were examined by confocal microscopy. Scale bars, 10µm. (B) 
Quantification of nuclear and cytoplasmic EGFP-tagged FUS intensity ± SD 
(n>200 cells) using ImageJ scripts. One Way Anova was performed to 
determine statistical significance. *p ≤0.05; **p≤0.005; ***p≤0.001; n.s: not 
significant. (C) The percentage of EGFP-positive cells with cytoplasmic 
inclusions (n > 100 cells). * p ≤0.001. (D)  N2A cells were transfected with 
EGFP-tagged WT, P525L, and P525L/K315Q/K316Q FUS. The nuclei were 
visualized with DAPI. Samples were examined by confocal microscopy. Scale 
bars, 10µm. (E) The percentage of EGFP-positive cells with cytoplasmic 
inclusions (n > 100 cells). * p ≤0.001. (F) N2A cells were transfected with 
EGFP-tagged WT or P525L FUS. One set of P525L transfected cells were 
treated with deacetylase inhibitor (DACi) cocktail (30 mM nicotinamide, 50 mM 
sodium butyrate and 3 µM Trichostatin-A).  The nuclei were visualized with 
DAPI. Samples were examined by confocal microscopy. Scale bars, 10µm. 
(G) The percentage of EGFP-positive cells with cytoplasmic inclusions (n > 








Figure 1.5. FUS acetylation mimicking mutant inclusions co-localize with the 
stress granule marker G3BP1.  
 
 Co-localization of endogenous G3BP1 with EGFP-tagged FUS in N2A 








Figure 1.6. Characterization of the anti-K510-acetylated FUS antibody.  
 
(A) HEK293T, N2A, and N2A-∆FUS (FUS knockout) cells were treated 
with deacetylase inhibitor (DACi) cocktail (30 mM nicotinamide, 50 mM sodium 
butyrate and 3 µM Trichostatin-A), as indicated.  Immunoblotting was 
performed using the indicated antibodies. (B) N2A ∆FUS cells were 
transfected with 3×FLAG-tagged WT, K510R, or K510Q FUS or vector control 
with or without DACi cocktail as indicated. Immunoblotting was performed 





Figure 1.7. K510 acetylation is increased in familiar FUS ALS.  
 
(A) FUS-K510 acetylation levels in ALS patients with R521G or P525R 
FUS mutations versus control subjects. Immunoblotting was performed using 
the indicated antibodies. (B) Quantification of FUS-K510 acetylation 
normalized against total FUS levels. Error bars represent SD between 
individuals. One Way Anova was performed to determine statistical 





Figure 1.8.  The regulators of FUS acetylation 
 
(A) 3×FLAG-FUS or 3×FLAG-vector was co-transfected with HA-CBP 
or HA-vector into N2A cells. FLAG immunoprecipitation was performed, 
followed by immunoblotting using the indicated antibodies. (B) N2A cells were 
treated with different concentrations of the CBP/p300 inhibitor A-485 in the 
presence of DACi cocktail. Immunoblotting was performed using the indicated 
antibodies (C) Quantification of (B), from three independent experiments ± SD. 
Student’s t-test was performed for individual comparisons against no 
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treatment. *p ≤0.05. (D) N2A cells were transfected with FLAG-vector or 
FLAG-FUS and treated with CBP/p300 inhibitor A-485 (8µM) for 16h in the 
presence of DACi cocktail.  FLAG immunoprecipitation was performed, 
followed by immunoblotting with the indicated antibodies. (E) N2A cells were 
transfected with FLAG-FUS and treated with 30 mM nicotinamide and/or 3 µM 
Trichostatin-A for 6h. FLAG immunoprecipitation was performed followed by 
immunoblotting with the indicated antibodies. (F) Quantification of (E), from 
three independent experiments ± SD. (0µM). *p ≤0.05. One-way Anova was 
performed to determine statistical significance. *, p ≤0.05; **, p≤0.005; (G) N2A 
cells were treated with 30 mM nicotinamide and/or 3 µM Trichostatin-A for 6h. 
Cells were harvested and lysed after treatment and immunoblotting was 
performed using the indicated antibodies. (H) Quantification of (G), from three 
independent experiments ± SD. One-way Anova was performed to determine 
statistical significance. *, p ≤0.05; **, p≤0.005; ***, p≤0.001; n.s,: not significant. 
(I) HEK293T cells were transfected with 3×FLAG-empty vector, 3×FLAG-
SIRTs 6-7, 3×FLAG-HDAC3, and 3×FLAG-ROA1 (hnRNPA1) used as a 
positive control. After 48h, endogenous FUS immunoprecipitation was 














Figure 1.9. Interaction screening of FUS with lysine deacetylases.  
 
(A) HEK293T cells were transfected with 3×FLAG-HDAC 1-11 (A) or 
3×FLAG SIRT 1-7 (B). After 48hrs, endogenous FUS immunoprecipitation was 
performed, followed by immunoblotting using the indicated antibodies. The 











Figure 1.10.  Proposed model of the role of FUS acetylation in the modulation of 
FUS subcellular localization and inclusion formation 
 
Acetylation of K315/K316 disrupts the RNA binding but does not 
interfere with the TNPO1-mediated nuclear import of FUS. In contrast, 
acetylation of K510 disrupts the interaction with TNPO1 and promotes the 
formation of cytoplasmic inclusions. When all three lysine residues are 
acetylated, FUS accumulates in the cytoplasm but forms less inclusions due 
to impaired RNA binding. We propose this process to be dynamic and the three 
forms of FUS acetylation can be present simultaneously. For ALS-linked 
mutations, mutant FUS shows reduced TNPO1 binding, impaired nuclear 





CHAPTER 2. FUS REGULATES THE TRANSCRIPTION OF GENES CRITICAL 
TO AUTOPHAGY 
2.1 Abstract 
FUS/TLS (Fused in Sarcoma/Translocated in Liposarcoma) is a 
ubiquitously expressed RNA-binding protein that has been reported to play 
different roles in the cell. Mutations in FUS have been linked to a subset of 
familial cases of the neurodegenerative disease amyotrophic lateral sclerosis 
(ALS). FUS is mainly localized in the nucleus, although it shuttles between the 
nucleus and the cytoplasm to transport RNAs, and it is also present in the 
cytoplasm of neuronal cells. [29]. Mutations in the nuclear localization 
sequence (NLS) of FUS, causes its mis-localization to the cytoplasm where it 
forms inclusions that co-localize with stress granule proteins. Stress granules 
are dynamic complexes that are form by proteins, ribosomes and RNAs, and 
they can be degraded by the autophagy pathway. It has been shown that 
stress granules containing mutant FUS co-localize with autophagosomes, 
however the role of FUS in this pathway needs to be elucidated. In this study 
we found that KO FUS cells had a decreased basal autophagy flux. Treatment 
with Bafilomycin A1 and rapamycin showed that KO FUS cells were not able 
to induce autophagy as efficiently as WT cells, suggesting that the initial 
phases of the autophagy pathway are affected in FUS KO cells. We found that 
FIP200, ATG16L1, and ATG12 mRNA and protein levels were significantly 
lower in FUS KO cells. Overexpressing FUS in FUS KO cells was able to 
rescue gene and protein expression levels of FIP200 and ATG16L1. Our 
findings demonstrate a novel role of FUS in the autophagy pathway, by 
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regulating the transcription of genes involved in the initial stages of autophagy, 
such as initiation and phagophore elongation.  
2.2 Introduction  
2.2.1 FUS in cytoplasmic inclusions and stress granules dynamics  
Many of the familial ALS-related FUS mutations are localized in the C-
terminal NLS, causing mis-localization of FUS to the cytoplasm where it forms 
inclusions that co-localize with stress granule proteins [82-85]. Cytoplasmic 
aggregates are a hallmark of neurodegenerative diseases, with neurofibrillary 
tangles (NFTs) in Alzheimer's disease (AD) [137], Lewi bodies in Parkinson’s 
disease (PD), or inclusion bodies in ALS tissue samples [138].  In fact, all 
sporadic and familial non-SOD1 ALS patients, display FUS inclusions in the 
spinal cord. These inclusions are also immunoreactive to TDP43, p62, and 
ubiquitin [139].  
Moreover, protein aggregation can be induced after cellular stress 
[140].  Stress granules are dynamic membrane-less cytoplasmic complexes of 
proteins, ribosomes, and RNAs that form under oxidative stress, hyperosmolar 
stress, or heat shock [141].  The precise role of stress granules remains to be 
fully understood, however it has been suggested that they can serve as 
storage sites for further mRNA translation or degradation [142]. Several 
studies have reported that mutant FUS inclusions, co-localized with stress 
granules markers [82, 83, 143-145]. A study showed that cells expressing 
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ALS-linked FUS mutations form cytoplasmic inclusions that co-localize with 
stress-granule proteins such as PABP1, TIA-1, G3BP1 [83, 146].  However, 
FUS is not required for stress granule assembly [145]. The previous evidence 
shows that FUS is involved in stress granule dynamics, and that alterations in 
this process by FUS mutations can lead to aberrant aggregation with other 
RNA-binding proteins and RNAs. Protein turn-over pathways, particularly 
autophagy, help clear pathogenic aggregates from the cells and maintain 
protein homeostasis.  
 
2.2.2 Autophagy pathway 
There are two major protein degradation pathways: the ubiquitin-
proteasome system (UPS) and the autophagy pathway. The UPS is 
responsible for the degradation of short-lived soluble proteins, while the 
autophagy pathway can degrade misfolded proteins and whole organelles 
[147] (The autophagy pathway is illustrated in Figure 2.1). 
mTOR is a well-known regulator of autophagy that acts as an inhibitor 
of the pathway when the cells are under nutrient-rich conditions, by preventing 
the formation of the autophagy initiation complex (ULK1-ATG13-FIP200). 
When starvation conditions hit the cells, or cells are treated with rapamycin, 
mTOR is inhibited and autophagy starts with activation of the initiation complex 
and formation of the phagophore [148].  
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Subsequently, elongation of the phagophore is facilitated by two 
ubiquitin-like systems: ATG12:ATG5:ATG16L system and PE-LC3 system. 
These two processes are governed by ATG (AuTophaGy-related proteins). 
The first complex receives autophagy initiation signals, and localizes to the 
autophagy isolation membrane for elongation [149]. A sequence of events that 
resemble the ubiquitin-proteasome pathway are involved in this step. First, 
Atg12 binds Atg5 through an E1-like enzyme Atg7. Then, Atg12-Atg5 
conjugates with Atg16L1 through the reaction with E2-like enzyme Atg10 
[149], resulting in the ATG12:ATG5:ATG16L system.  
Similarly, PE-Atg8 system is in charge of Atg8 processing. Atg8 (LC3) 
is synthesized with an extra C-terminus sequence that is removed by Atg4. 
This process helps to expose the glycine residue of Atg8 (LC3-I), that is 
required for the next steps of the reaction.  Then, Atg7 and Atg3 activate Atg8, 
in order to attach phosphatidylethanolamine (PE) to the Atg8-C-terminal 
glycine (LC3-II). PE is necessary for the attachment of this protein to the 
phagophore membrane. Finally, Atg12-Atg5-Atg16L1 and Atg8-PE function 
synergistically to promote autophagosome elongation [150].  
When the phagophore elongates and encloses the targeted misfolded 
proteins, or damaged organelles, it forms a double-membraned 
autophagosome [151].  Afterwards, Atg12-Atg5-Atg16L disassembles from the 
membrane, but LC3-II remains attached in the autophagosome membrane 
until the latest steps of the pathway. Thus, LC3-II is a good marker to evaluate 
autophagy flux [152].  
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Finally, the mature autophagosome fuses with the lysosome, and its 
contents are degraded by acidic proteases. Subsequently, the amino acids 
and other by-products of the degradation are recycled back into the cytoplasm, 
where they can be re-used for cell metabolism [153]. 
  
2.2.3 Autophagy and ALS  
Neurons are post-mitotic cells that are highly susceptible to protein 
aggregation, thus defects in protein homeostasis are particularly detrimental 
for neurons. The balance between protein folding, assembly and degradation 
is necessary for the normal function of the cells [154] This balance is 
maintained by several factors, including proteolytic machinery and protein 
chaperones [155, 156].  
Defects in the autophagy pathway have been reported in 
neurodegenerative diseases such Alzheimer’s disease and ALS [157-159]. A 
pathological characteristic of ALS is the accumulation of insoluble protein 
aggregates in the cytoplasm of motor neurons [154]. Under normal conditions, 
when protein aggregates form, cells have quality control mechanisms to 
degrade misfolded proteins, to prevent protein aggregation, or to clean up 
aggregates that have already formed [147]. However, under pathological 
conditions, cytoplasmic aggregates result from misfolded proteins that lose 
their native conformations and fail to be cleared from the cell by the ubiquitin-
proteasome pathway or autophagy [147]. The common phenotype of protein 
61 
 
aggregation in neurodegenerative diseases suggests that the mechanisms to 
maintain protein homeostasis are disrupted and that cytoplasmic aggregates 
become aberrant and might contribute to cytotoxicity [147].  
Some studies have found evidence that autophagy dysregulation might 
be associated to ALS. For instance, a study analyzed post-mortem samples 
from sporadic ALS patients and found that cytoplasmic inclusions in motor 
neurons were immunoreactive to p62 and LC3-II [160]. In another study, p62-
positive inclusions were found in iPSCs derived from patients with C9orf72 
expansion [161]. Interestingly, when autophagy was inhibited by chloroquine 
treatment, cell viability decreased in these cells. In another study involving 
iPSCs derived from ALS/FTLD patients with C9orf72 haploinsufficiency, LC3-
II autophagy flux as significantly reduced [162]. Together, these studies 
suggest that autophagy is essential for maintaining protein homeostasis in 
neuronal cells.  
In a performed in SOD1 G93A mice, an autophagy inducer lithium was 
found to delay the disease onset and increase the life span. The 
neuroprotective effects were coupled with the autophagy activation and a 
larger number of mitochondria in motor neurons [163]. Interestingly, a pilot 
study in 44 ALS patients with no placebo-controls showed that patients treated 
with lithium carbonate survived until the end of the study while 29% of patients 
treated with riluzole died by the same time [163]. These results suggest that 
autophagy induction might provide a protective effect for neurodegeneration. 
However, a multicentre, randomised, double-blind, placebo-controlled clinical 
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trial found that, although there were no safety concerns, there was no evidence 
of benefit of lithium on survival in patients with ALS (cite: Lancet Neurol. 2013 
Apr; 12(4): 339–345.). Thus, the clinical efficacy of the autophagy inducer 
lithium in ALS remains unclear.  
A study showed that autophagy deficient mouse embryonic fibroblasts 
(MEFs) showed an increase in mutant FUS-positive stress granules. In 
addition, stress granules that contain mutant FUS co-localize with 
autophagosomes [157]. Furthermore, induction of autophagy by rapamycin 
treatment in mutants FUS cells, reduced stress granule formation and cell 
death in neurons [157] . These results suggest that the autophagy pathway is 
important for clearance of mutant FUS cytoplasmic inclusions.  In another 
study, post-mortem tissue from sporadic adult-onset ALS showed basophilic 
inclusions that were immunoreactive for p62, LC3, and FUS [164]. A recent 
study showed that mutant FUS disrupts autophagy by affecting the formation 
of the omegasome [165], a membrane derived from the ER, and sites where 
phagophores form [166]. Together, these studies indicate that autophagy is an 
important mechanism involved in neurodegeneration, and dysregulation of this 
pathway may cause negative effects in motor neurons, leading to diseases 
such as ALS.  
2.2.4 Study rationale 
In summary, neurodegenerative diseases are characterized for toxic 
protein aggregation in the cytoplasm of neuronal cells. Since these are post-
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mitotic cells that do not undergo cell division, they are susceptible to defects 
in protein homeostasis. A few studies have shown a connection between FUS 
and the autophagy pathway. However, the specific function of FUS in this 
pathway remain to be studied. Here, we asked whether mutant FUS disrupts 
autophagy flux, and whether loss of FUS affects the expression of proteins 
involved in various stages of autophagy.  
2.3 Materials and Methods  
2.3.1 Cell culture and transfection 
N2A, FUS KO N2A, and NSC34 cells were cultured in Dulbecco’s Modified 
Eagle’s Medium (Sigma-Aldrich, D5796) with 10% fetal bovine serum, penicillin-
streptomycin, and amphotericin B at 37°C in 5% CO2/95% air with humidification. The 
pCMV10-3×FLAG-FUS plasmids, were generated as reported [83]. Cells were treated 
with bafilomycin A1 (200nM) for 6 hours, Rapamycin (2µM) for 4h, or MG-132 (5µM) 
for 16 hours. FUS mutations were introduced using the QuickChange II Site-Directed 
Mutagenesis Kit (Agilent). N2A, FUS KO N2A and NSC34 cells were transfected with 
Lipofectamine 2000 (Thermo Fisher Scientific, 11668). siRNA-FUS (Santa Cruz, sc-
40563) oligonucleotides were reversed-transfected into N2A and NSC34 cells at a 
final concentration of 1µM using Lipofectamine™ RNAiMAX (Thermo Fisher 




2.3.2 Generation of FUS KO (∆FUS) N2A cells.  
The FUS knockout cells were generated by employing CRISPR 
technology. N2A cells were transfected with FUS double nickase CRISPR 
plasmid (Santa Cruz Biotechnology, sc-433326-NIC) following the 
manufacturer’s instructions. Clonal cell lines were isolated with serial dilution, 
and the FUS status of the clones was determined with immunoblotting. 
 
2.3.3 Generation of the FLAG-FUS knock-in cells lines  
 FLAG-tagged FUS WT was transfected into FUS KO N2A cells using 
Lipofectamine 2000 as described above. Selection of stable cells with FLAG-
FUS WT integration was performed with G-418 (Millipore Sigma G418-RO). 
Clonal cells lines were isolated with serial dilution, and the FUS expression 
levels were compared to endogenous FUS in N2A cells by western blot, using 
anti-FUS and anti-FLAG antibodies.  
 
2.3.4 Western blot analysis  
Cells were lysed with 1x RIPA buffer (Millipore Sigma, 20-188) 
supplemented with protease inhibitor cocktail (Millipore Sigma, P8340, 1:500) 
and sodium orthovanadate (1 mM). Lysates were homogenized by sonication 
and centrifuged at 1,000g for 15 minutes at 4°C. Supernatant was collected 
and protein concentration was determined using a colorimetric Protein Assay 
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Dye Reagent Concentrate (BIO-RAD, 5000006,). 6x SDS buffer sample was 
added to samples containing equal amounts of protein and heated for 5 min at 
95ºC. Proteins were resolved by SDS-PAGE and transferred to nitrocellulose 
membranes (Pall, 66485). The membranes were blocked with 5% non-fat dry 
milk in TBST (100 mM Tris-HCl, pH 7.5, 0.9% NaCl, 0.1% Tween-20) or bovine 
serum albumin (BSA) for 1 hour.   
2.3.5 Antibodies 
The antibodies used include mouse anti-FUS (Santa Cruz, sc-47711), 
mouse monoclonal ANTI-FLAG® M2-Peroxidase (HRP) (Millipore Sigma, 
A8592), rabbit anti-β-actin (Cell Signaling 8457). LC3 (Millipore Sigma L8918), 
Mouse anti-SQSTM-p62 (H00008878-M01), Autophagy Induction (ULK1 
Complex) Antibody Sampler Kit (Cell Signaling 46486,) containing ULK1 
(D8H5) Rabbit mAb (Cat #8054), Atg13 (D4P1K) Rabbit mAb (Cat# 13273), 
FIP200 (D10D11) Rabbit mAb (Cat#12436), Atg101 (E1Z4W) Rabbit mAb 
(Cat#13492), Phospho-ULK1 (Ser757) (D7O6U) Rabbit mAb (Cat#14202), 
Phospho-ULK1 (Ser555) (D1H4) Rabbit mAb (Cat#5869). Autophagy 
Antibody Sampler Kit (Cell Signaling, 4445) containing Beclin-1 (D40C5) 
Rabbit mAb (Cat#3495), Atg5 (D5F5U) Rabbit mAb (Cat#12994), Atg12 
(D88H11) Rabbit mAb (Cat#4180), Atg16L1 (D6D5) Rabbit mAb (Cat#8089), 




2.3.6 TaqMan qPCR Assay 
RNA isolation was performed using Aurum Total RNA Mini Kit (BIO-
RAD, 732-6820) following the manufacturer’s instructions. 1µg of isolated RNA 
was reverse transcribed using the SuperScript III First-Strand Synthesis 
System (Thermo Fisher Scientific, 18080). The resulting cDNA was subjected 
to Real-time PCR. Briefly, FAM-labeled Taqman probes for autophagy related 
genes and controls were obtained from the TaqMan Gene expression assay 
library from ThermoFisher Scientific.  TaqMan® Fast Advanced Master Mix 
(ThermoFisher Scientific, 4444556, Thermo Fisher Scientific) was prepared 
following manufacturer’s instructions. The assay IDs for the FAM-labelled 
probes analyzed are: Mm00456545_m1 (Rbcc1, FIP200), Mm00509659_m1 
(Atg101), Mm00512209_m1 (Atg7), Mm00471287_m1 (Atg3), 
Mm00503201_m1 (Atg12), Mm00513085_m1 (Atg16L1), Mm01612987_g1 
(Rpl13a), Mm99999915_g1 (GAPDH), Mm00607939_s1 (Actin). The qPCR 
results were analyzed using the ∆∆CT method.  
 
2.3.7 Statistical analysis 
Lane quantification for Western blot bands was performed using Image 
Lab software by BioRad. Statistical analysis was calculated with SigmaPlot 
14.0 software. Band intensities were calculated and comparison between 
groups was performed using Anova with post hoc Tuckey HSD test. Student’s 
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t test was used to determine statistical significance between two groups. 
Experiments were not blinded. All experiments were done in triplicates. 
2.4 Results 
2.4.1 ALS-linked mutant FUS did not affect autophagy 
First, we tested whether the ALS-linked FUS mutations would affect the 
levels of basal autophagy. FUS KO N2A cells were transfected with FLAG-
tagged WT, R495X, R521G, or P515L FUS. The levels of autophagy markers 
LC3-I, LC3-II, and p62 were subsequently analyzed by Western blot. To our 
surprise, the LC3-II/LC3-I ratios and the p62 level did not change between any 
mutant FUS as compared to WT FUS (Figure 2.2 A-B), indicating that mutant 
FUS did not affect the autophagy flux.   
2.4.2 FUS knockout reduced the basal level of autophagy  
We next examined whether the absence of FUS would affect the 
autophagy pathway. We used siRNA to knockdown FUS and evaluated the 
levels of autophagy markers LC3-I and LC3-II. The LC3-II/LC3-I ratio was 
reduced in the FUS knockdown cells as compared to WT cells (Figure 2.3A). 
We tested the LC3-I and LC3-II levels in FUS KO N2A cells and obtained a 
similar result that the LC3-II/LC3-I ratio decreased in the FUS KO cells (Figure 
2.3B). Together, these data suggest that FUS might be an important player 
during autophagy initiation, phagophore elongation, or autophagy flux.  
To test whether FUS plays a role in the autophagy initiation, 
phagophore elongation, or autophagy flux stage, we treated N2A and N2A 
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FUS KO cells with bafilomycin A1 or rapamycin, followed by Western blots of 
autophagy markers. Bafilomycin A1 disrupts the late stages of the autophagy 
flux by inhibiting the autophagosome-lysosome fusion and preventing 
autolysosome acidification [167]. Consistent with earlier results, the ratio of 
LC3-II/LC3-I was significantly lower in FUS KO cells as compared to WT cells 
without Bafilomycin A1 (Figure 2.3C-D). After the Bafilomycin A1 treatment 
(200 nM, 6 hrs), the LC3-II/LC3-I ratio increased significantly in WT N2A cells 
(Figure 2.3C, lane 2 vs lane 1) as well as FUS KO cells (Figure 2.3C, lane 4 
vs lane 3). However, even in the presence of Bafilomycin A1, the LC3-II/LC3-
I ratio was still significantly lower in FUS KO cells compared to WT cells (Figure 
2.3C, lane 4 vs lane 2). These results suggest that FUS KO did not affect the 
late stages of autophagosome-lysosome fusion or autophagy flux, but rather 
affected the early stages of the autophagy pathway.  
Rapamycin is a well-stablished mTOR inhibitor that induces the 
initiation of autophagy [168]. After the Rapamycin treatment (2 µM, 4 hrs), the 
LC3-II/LC3-I ratio significantly increased in WT N2A cells as compared to non-
treatment (Figure 2.3E-F, lane 2 vs lane 1). In contrast, the LC3-II/LC3-I ratio 
did not change in FUS KO cells in the presence of rapamycin (Figure 2.3E-F, 
lane 4 vs lane 3), suggesting that FUS KO cells were not able to respond to 




2.4.3 FUS affected the levels of proteins critical in early phases of autophagy  
We next analyzed the expression of proteins involved in the ULK1 
initiation complex that is composed of ULK1, Atg13, Atg101 and FIP200. This 
complex promotes or suppresses the autophagy process depending on the 
nutrient status of the cell [169]. We tested the expression of Atg13, Atg101, 
FIP200, total ULK1 and phosphorylated ULK1 in WT and FUS KO N2A cells 
(Figure 2.4A-B). Atg13, Atg101, total ULK1 expression did not change 
between WT and FUS KO cells. The phosphorylation on UKL1 Ser757 or 
Ser555 did not change in FUS KO cells either (Figure 2.4C). Interestingly, 
FIP200 expression was significantly reduced in FUS KO cells as compared to 
WT cells (Figure 2.4A-B).  
We also evaluated the proteins involved in the phagophore elongation 
[150]: Atg3, Atg5, Atg12, Atg7 and Atg16L1 (Figure 2.4D-E). Atg3, Atg16L1, 
and the Atg5-Atg12 complex showed a significant decrease in FUS KO cells 
as compared to WT cells. However, the protein level of Atg5 alone did not 
change between FUS KO and WT cells, indicating that only Atg12 protein was 
affected in the absence of FUS. Similarly, Atg7 did not change in FUS KO 
cells. Taken together, these results suggest that FUS likely plays an important 
role in the autophagy initiation and phagophore elongation stages by 





2.4.4 FUS regulated the transcription of genes involved in early phases of 
autophagy 
Since FUS regulated the protein levels, we examined whether FUS 
might regulated the transcription of corresponding genes involved in the initial 
phases of autophagy using quantitative RT-PCR. For genes involved in the 
autophagy initiation, the mRNA levels of FIP200 showed a significant 
decrease (~57%) in FUS KO cells (Figure 2.4F) while Atg101 and Atg7 mRNA 
levels did not significantly change between the two groups. For genes involved 
in the phagophore elongation, the mRNA levels of Atg3 (~48%), ATG16L1 
(~54%), and Atg12 (~48%) decreased significantly in FUS KO cells (Figure 
2.4G). Atg7 was used as a negative control and did not change significantly. 
These results suggest that FUS likely plays a role in regulating the gene 
expression of those critical to the autophagy initiation and phagophore 
elongation.  
 
2.4.5 FUS knock-in restores expression of autophagy related genes.  
 To further solidify our conclusion, we examined whether re-
expression of FUS in the FUS KO cells can restore the expression of the 
affected autophagy related genes. To this end, we generated a cell line that 
stably expresses FLAG-tagged WT FUS in N2A-FUS KO cells, hereby named 
FUS knock-in (KI) cells. The expression level of FUS in the FUS KI cells was 
comparable in WT N2A cells. FUS KI significantly restored the protein levels 
of Atg16L1 (100%) and FIP200 (~80%) as compared to FUS KO cells (Figure 
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2.5A-B). Similarly, FUS KI also increased the mRNA levels of Atg16L1 and 
FIP200 as compared to the FUS KO cells (Figure 2.5C). The mRNA levels of 
Atg16L1 and FIP200 were restored to ~60% in WT N2A cells. The results 
support that FUS plays a role in regulating the transcription of the genes 
involved in the autophagy initiation and phagophore elongation.  
 
2.5 Discussion 
FUS is a DNA/RNA binding protein that has been linked to familial 
cases of ALS , and its pathology has been reported in FTD patients [114]. 
Research has found that FUS plays multiple roles in various pathways inside 
the cell. We hereby report a previously unknown function of FUS, i.e. FUS 
regulates the initiation of autophagy by mediating the transcription of genes 
that are critical to autophagosome formation.  
We found that the expression of mutant FUS did not change the levels 
of autophagy markers (Figure 2.2). The role of autophagy in FUS mediated 
ALS has been debated. One study reported that impairment of the proteasome 
pathway replicated ALS phenotypes in mice with TDP-43 and FUS 
proteinopathy, but impairment of the autophagy pathway by motor neuron-
specific knock-out of Atg7 did not show ALS phenotype [170]. However, 
another study showed that torkinib, an autophagy-enhancing compound that 
functions as an mTOR inhibitor, reduced FUS cytoplasmic aggregates and 
rescued motor function in P525L iPSC-derived motor neurons [171]. Thus, it 
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remains possible that both UPS and autophagy pathways contribute to the 
degradation of toxic protein aggregates in various experimental systems in 
neurodegenerative diseases [172].  
Our results showed that overexpression of mutant FUS did not affect 
autophagy in N2A cells, which is supported by a study showing that the 
expression of FUS mutant R521C did not impair autophagy [157]. However, 
another study reported that overexpressing mutant FUS impairs autophagy by 
disrupting early stages of Rab-1 dependent autophagy pathway [173]. It is 
possible that mutant FUS affected the autophagy pathway differently in 
different experimental systems.  
More interestingly, FUS knockdown or knockout cells showed 
significantly decreased levels of autophagy flux marker (Figure 2.3A-B). 
Moreover, the FUS knockout cells did not respond to rapamycin treatment as 
WT cells did (Figure 2.3E-F). Consistently, the level of LC3-II increased in the 
presence of Bafilomycin A1, but the level in FUS knockout cells was 
significantly lower than that in WT cells (Figure 2.3C-D). The results suggest 
that FUS is involved in the LC3-II lipidation, phagophore elongation and 
autophagosome formation.  
Furthermore, we demonstrated that the mRNA and protein levels of 
FIP200, Atg3, Atg16L1 and Atg12 decreased in FUS KO cells (Figure 2.4), 
which were restored by expression of FUS (Figure 2.5). ULK1, FIP200 and 
Atg13 form a complex that is required for ULK1 localization to the isolation 
membrane and subsequent phagophore formation [174-176]. Atg101 is 
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associated with the ULK1 complex by interacting with Atg13 [177]. Among the 
four genes/proteins examined, only FIP200 was affected by FUS KO. FIP200 
has been reported to be an essential regulator of autophagy in Drosophila 
melanogaster [178] and mammalian cells [179]. In both studies, when the 
FIP200 was silenced, the induction of autophagy activity was severely 
impacted. Thus, we conclude that the regulation of FIP200 expression by FUS 
is a critical mechanism in autophagy initiation. 
Atg (AuTophaGy-related) genes function as a ubiquitin-like conjugation 
system to facilitate LC3-II lipidation and phagophore elongation [150]. Among 
five Atg genes examined in this study, the levels of Atg3, Atg16L1 and Atg5-
Atg12 complex decreased consistently. The Atg5-Atg12 complex conjugates 
with Atg16L1 [180] and facilitate the attachment of phosphatidylethanolamine 
(PE) to the C-terminal glycine of Atg8 (LC3) [149], which promotes phagophore 
elongation [150, 181, 182]. These studies support our model (Figure 2.6) that 
FUS regulates the expression of genes critical to LC3 lipidation, phagophore 
elongation, and autophagosome formation.  
It is noted that it is yet to be determined in future studies how FUS 
regulates the expression of FIP200, Atg3, Atg16L1 and Atg12 genes. FUS was 
reported to be associated with active chromatin [48], to interact with nuclear 
receptors [61], transcription factors [60], and RNA polymerase II and the TFIID 
complex [44], suggesting that FUS is part of the transcription machinery. 
However, it is unclear how FUS specifically regulate these genes while it does 
not change other Atg genes. It is conceivable that there are specific elements 
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in the regulatory region of these genes that specifically interact with FUS. 
Future studies are needed to determine such FUS-interacting elements for 
those genes.  
Our study discovered a novel function of FUS in protein homeostasis. 
Specifically, FUS regulates the early stages of autophagy by modulating the 
transcription of genes that play a role in autophagy initiation (FIP200) and 
phagophore elongation (Atg12 and Atg16L1). The lack of FUS causes the 
downregulation of the gene expression and protein levels, leading to 
decreased phagophore formation, and thus the reduction in basal autophagy 
flux (Figure 2.6). The function of FUS in autophagy in vivo remains to be further 
examined in future studies. The significance of FUS regulation of autophagy 
genes in the context of neurodegenerative diseases such as ALS and FTD is 












Figure 2.1. The autophagy pathway. 
 
mTORC is a negative regulator of autophagy. Under normal conditions 
mTORC inhibits autophagy, however under starvation or after rapamycin 
treatment, mTORC is inhibited and autophagy starts. The ULK initiation 
complex starts downstream signaling for the generation of the phagophore. 
Then, the phagophore elongates by the action of Atg12:Atg5:Atg16L and PE-
Atg8 conjugation system. The phagophore encloses the cargo that needs to 
be degraded forming a mature autophagosome that fuses with a lysosome. 
The lysosome releases acidic proteases that degrade the cargo. Finally, the 






Figure 2.2 Mutant FUS does not affect basal autophagy  
 
 (A) FUS knockout N2A cells were transfected with FLAG-tagged 
vector, WT FUS, FUS-R495X, R521G, P525L. 48h after transfection cells 
were collected and immunoblotting was performed with the indicated 
antibodies. (B) Quantification of (A) from three independent experiments ± SD. 
Student’s t-test was performed for individual comparisons against FLAG-FUS 

































Figure 2.3 Basal autophagy is affected in FUS KO cells 
 
(A) N2A cells were transfected with FUS siRNA using Lipofectamine™ 
RNAiMAX. 48h after transfection cells were harvested and immunoblotting 
was performed using the indicated antibodies. (B) N2A and FUS knockout 
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(KO) N2A cells were cultured and immunoblotting was performed using the 
indicated antibodies. (C) N2A and KO cells were treated with Bafilomycin A1 
(200 nM) for 6h. Cells were harvested, and immunoblotting was performed 
with the indicated antibodies. (D) Quantification of (C) from three independent 
experiments ± SD. One Way Anova was performed to determine statistical 
significance. *p ≤0.05; **p≤0.005. (E) N2A and KO cells were treated with 
Rapamycin (2µM) for 4h. Cells were harvested, and immunoblotting was 
performed with the indicated antibodies. (F) Quantification of (E) from three 
independent experiments ± SD. One Way Anova was performed to determine 
























Figure 2.4. FUS regulates transcription of genes involved in autophagy initiation 




(A) N2A and FUS knockout (KO) N2A cells were cultured and 
immunoblotting was performed using the indicated antibodies. (B-C) 
Quantification of (A) from three independent experiments ± SD. Student’s t-
test was performed for individual comparisons against N2A WT cells. *, p 
≤0.05. (D) N2A and KO cells were cultured, and immunoblotting was 
performed using the indicated antibodies. (E) Quantification of (D) from three 
independent experiments ± SD. Student’s t-test was performed for individual 
comparisons against WT N2A WT cells. *, p ≤0.05. (F-G). N2A and KO cells 
were cultured and harvested for RNA isolation, followed by reverse 
transcription and quantitative PCR using TaqMan probes for the indicated 
genes. Actin was used to normalize the protein expression. Averages of three 
independent experiments are shown, ± SD. Student’s t-test was performed for 
































Figure 2.5. FUS knock-in restores expression of autophagy related genes. 
 
(A) N2A, FUS knockout (KO), and FUS knock-in (KO + WT) cells were 
cultured, and immunoblotting was performed using the indicated antibodies. 
(B) Quantification of (A) from three independent experiments ± SD. One Way 
Anova was performed to determine statistical significance. *p ≤0.05; 
**p≤0.005; n.s: not significant. (C) N2A, KO, KO + WT cells were cultured and 
harvested for RNA isolation, followed by reverse transcription and quantitative 
PCR using TaqMan probes for the indicated genes. Actin probe was used to 
normalize gene expression. Averages of three independent experiments are 
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shown, ± SD. Student’s t-test was performed for individual comparisons 










Figure 2.6. Proposed model of the role of FUS in the autophagy pathway 
 
We propose that FUS is involved in transcription regulation of genes 
involved in autophagy initiation and phagophore elongation. Lack of FUS in 
the cells causes downregulation at the gene expression and protein levels, 
causing a decrease in autophagosome formation, and thus the reduction in 




CHAPTER 3. CONCLUSIONS AND FUTURE DIRECTIONS 
Altogether, my work showed two novel characteristics of FUS in the cell. 
In the first chapter of this dissertation, we showed that FUS can be post-
translationally modified by lysine acetylation. Furthermore, we were able to 
identify the acetylated lysine residues in the RRM domain and C-terminal NLS. 
We showed that acetylation in K315/K316 in the RRM domain reduced the 
RNA binding capabilities of FUS. Additionally, we demonstrated that 
acetylation in the NLS affected the interaction between FUS and Transportin-
1, changing FUS subcellular localization and inducing the inclusion formation. 
Interestingly, we found that ALS patient-derived fibroblasts had increased 
acetylation at K510, suggesting that the acetylation at this site might be 
important in the ALS pathology. The acetylation-mimic mutation in the RRM 
domain and treating cells with the deacetylase inhibitor reduced the number of 
cells containing cytoplasmic inclusions in cells expressing the ALS mutant 
FUS P525L. We also found that CBP/p300 acetylated FUS, more specifically 
K510, and found that HDACs and SIRTs played a role in FUS deacetylation.  
Our study shows a novel mechanism by which FUS can be regulated 
and provides a new avenue for potential therapeutic development in the future. 
The fact that FUS acetylation on its RRM domain reduces inclusion formation 
in cells expressing mutant FUS suggests that deacetylase inhibitors could be 
targeted to this domain in order to prevent aberrant aggregation of FUS in the 
cytoplasm in ALS patients. In addition, preventing acetylation in the NLS can 
restore the interaction with Transportin-1 and promote FUS nuclear 
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localization. Interestingly, we found that ALS patients have higher levels of 
acetylation at K510. CBP/p300 acetylates this lysine K510 with higher 
specificity, thus we propose that CBP/p300 inhibitor A-485 might serve as a 
possible target for future pharmaceutical studies for ALS treatment.   
Although this study shows promising findings on FUS regulation, further 
investigation is needed to characterize the molecular mechanism that controls 
FUS acetylation and the functional consequences of this PTM in different 
biological processes where FUS is actively involved. Additional studies are 
needed to explore the role of FUS acetylation in modulating protein translation 
and NMD pathway, for instance by testing changes in NMD markers when 
FUS is acetylated. Since we noticed a change in cytoplasmic aggregation 
when FUS is acetylated, it would be interesting to examine how acetylation 
can affect stress granule dynamics, and whether FUS acetylation changes the 
assembly or disassembly of cytoplasmic aggregates.   
The second chapter of this dissertation showed a novel role of FUS in 
the autophagy pathway. We found that the ALS mutant FUS did not affect 
autophagy flux. However, FUS KO cells showed decreased levels of LC3-II 
and were not able to induce autophagy as efficiently as WT N2A cells. We 
found that proteins involved in autophagy initiation and phagophore elongation 
were lower in FUS KO cells. Furthermore, we found that the transcription of 
genes encoding for these proteins were also downregulated. Finally, the 
protein and mRNA levels of affected genes were rescued when WT FUS was 
overexpressed in KO cells. 
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Previous studies had demonstrated that FUS inclusions co-localized 
with autophagosomes and LC3-II marker, suggesting that cytoplasmic protein 
aggregates are degraded by the autophagy pathway [157]. However, in this 
study we found that FUS is a novel player in regulating autophagy. Our data 
indicate that FUS affects transcription of FIP200 and ATG16L1, however 
future studies are needed to elucidate the mechanism by which such 
transcription downregulation occurs. As discussed in Chapter 1, FUS is 
involved in a variety of nuclear functions, including transcription, splicing, and 
miRNA processing. All these mechanisms can affect gene expression; thus, it 
is necessary to perform next generation sequencing in WT and KO FUS cells 
to differentiate gene expression patterns between these two cell populations. 
Additionally, it can be useful to determine whether the promoter regions of the 
autophagy-related genes contain consensus sequences where FUS can bind 
to and regulate transcription.  
The two novel findings described in this dissertation may affect each 
other although currently there is no evidence. We found that FUS acetylation 
at K510 disrupts the interaction with TNPO1, preventing FUS to be shuttled 
into the nucleus and promoting FUS accumulation in cytoplasmic aggregates. 
A loss-of-function of FUS in the nucleus would disrupt nuclear processes in 
which FUS plays an important role, including transcription. It is conceivable 
that a loss-of-function in the nucleus would disrupt the transcription of 
autophagy genes. Consequently, the autophagy pathway would be impacted, 
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and the cells will not be able to clear out cytoplasmic aggregates efficiently. 
This hypothesis can be tested in future studies.  
Overall, the two projects described in this dissertation open a new 
avenue of research that can be further explored and can be translated into 
therapeutic interventions. Both projects provide novel insights into the role of 
FUS in neurodegenerative diseases, including ALS and FTD. Further 
investigation in this field is necessary to find the connection between these two 
studies, for instance, to explore how the effect of FUS acetylation on protein 
function and inclusion formation will impact the transcription of genes involved 
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